

424/Rec'd PCT/PTO 10 MAR 2000

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (if known see 37 C.F.R. 1.5)

09/508487

INTERNATIONAL APPLICATION NO.

PCT/IB98/01424

INTERNATIONAL FILING DATE

4 September 1998

(EARLIEST) PRIORITY DATE CLAIMED

10 September 1997

TITLE OF INVENTION

P13 ANTIGENS FROM BORRELIA

APPLICANTS FOR DO/EO/US

Sven BERGSTRÖM

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)), including \_\_\_\_\_ sheets of formal drawings and a copy of the International Search Report.
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventors (35 U.S.C. 371(c)(4)).
10. ☐ The annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern other document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

Check No. 9353 for \$2036.00 for filing fee

Check No. 9354 for \$40.00 for assignment recordal

**EXPRESS MAIL**

Mailing Label Number: EL375382479US

Date of Deposit: March 10, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service

"Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents and Trademarks, Box PCT Washington, DC 20231.

*Eduard Nay*

(Typed or printed name of person mailing paper or fee)

*Eduard Nay*  
(Signature of person mailing paper or fee)

09/508487

PCT/IB98/01424

430 Rec'd PCT/PTO

10 MAR 2000

17. ☒ The following fees are submitted:

(CALCULATIONS /PTO USE ONLY)

**Basic National Fee (37 CFR 1.492(a)(1)-(5):**

Search Report has been prepared by the EPO or JPO.....\$840.00 (\$840.00)

International preliminary examination fee paid to USPTO (37 CFR 1.482) (

No international preliminary examination fee paid to USPTO (37 CFR 1.482) (

Neither international preliminary examination fee (37 CFR 1.482) nor (

International preliminary examination fee paid to USPTO (37 CFR 1.482) (

ENTER APPROPRIATE BASIC FEE AMOUNT =

(\$840.00)

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 (\$ /

months from the earliest claimed priority date (37 CFR 1.492(e)).

72 Claims /Number Filed / Number Extra /Rate (

Total Claims / 72 - 20 = / 52 /X \$18.00 (\$936.00/

Independent Claims / 2 - 3 = / 0 /X \$78.00 (\$ /

Multiple dependent claim(s) (if applicable) /+ \$260.00 (\$260.00/

**TOTAL OF ABOVE CALCULATIONS =**

(\$2036.00/

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity ( /

statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28). ( /

**SUBTOTAL =**

(\$2036.00/

Processing fee of \$130.00 for furnishing the English translation later than ( /

☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).+ (\$ /**TOTAL NATIONAL FEE =**

(\$2036.00/

Fee for recording the enclosed assignments (37 CFR 1.21(h)). The assignment (\$40.00 /

must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + (\$ /

**TOTAL FEES ENCLOSED =**

(\$2076.00 /

(Amount to be: /

(refunded /\$

(charged /\$

a. ☒ Our checks in the amount of \$2076.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. 50-0320 in the amount of \$\_\_\_\_\_ to cover the above fees.

A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0320. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

THOMAS J. KOWALSKI, ESQ.  
FROMMER LAWRENCE & HAUG LLP  
745 FIFTH AVENUE  
NEW YORK, NEW YORK 10151

SIGNATURE

THOMAS J. KOWALSKI  
NAME

Dated: March 10, 2000

32,147  
REGISTRATION NUMBER

Form PTO-1390 (REV 10-96)

430 Rec'd PCT/PTO 454312-3150 10 MAR 2000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s)	:	Sven Bergström
Filed	:	Herewith
Corresponding Int'l or Priority Applications	:	PCT/IB98/01424 Denmark 1041/97 U.S. Ser. No. 60/059,036
Priority Date	:	September 10, 1997
For	:	P13 ANTIGENS FROM BORRELLIA

745 Fifth Avenue  
New York, NY 10151

**EXPRESS MAIL**

Mailing Label Number: EL375382479US

Date of Deposit: March 10, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

Edward Nay

(Typed or printed name of person mailing paper or fee)

Edward J. [Signature]  
Signature of person mailing paper (or fee)

(Signature of person mailing paper or fee)

## **PRELIMINARY AMENDMENT**

Box PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Preliminary to the examination of this U.S. application, please enter the following:

**IN THE CLAIMS:**

Please amend the claims as follows:

Claim 1, line 14: after “conditions” insert --, i.e. 5-10°C under the melting point

$T_m$ --;

Claim 3, line 1: delete “or 2”;

Claim 4, line 1: change “any of the preceding claims” to --claim 1--;

Claim 5, line 1: change “any of the preceding claims” to --claim 1--;

Claim 6, line 1: change “any of the preceding claims” to --claim 1--;

Claim 7, line 1: change “any of the preceding claims” to --claim 1--;

Claim 8, line 1: change “any of the preceding claims” to --claim 1--;

Claim 9, line 1: change “any of the preceding claims” to --claim 1--;

Claim 12, line 1: change “any of the preceding claims” to --claim 1--;

Claim 13, line 1: change “any of the preceding claims” to --claim 1--;

Claim 16, line 1: change “any of claims 1-13” to --claim 1--;

Claim 18, line 1: delete “or 17”;

Claim 19, line 1: change “any of the preceding claims” to --claim 1--;

Claim 22, line 1: delete “or 21”;

Claim 23, line 1: change “any of claims 20-22” to --claim 20--;

Claim 24, line 1: change “any of claims 20-23” to --claim 20--;

Claim 25, line 1: change “any of claims 20-24” to --claim 20--;

Claim 26, line 1: change “any of claims 20-25” to --claim 20--;

Claim 28, line 1: delete “or 27”;

Claim 29, line 1: change “any of claims 20-28” to --claim 20--;



Claim 30, line 1: change “any of claims 20-29” to --claim 20--;

Claim 33, line 2: change “any of claims 20-32” to --claim 20--;

Claim 35, line 1: delete “or 34”;

Claim 36, line 1: change “any of claims 1-19” to --claim 1--;

Claim 39, line 1: change “any of claims 36-38” to --claim 36--;

Please amend Claim 40 as follows:

40. A vector according to [any of claims 36-39] claim 36, wherein the vector comprises, in the 5'→3' direction and in operable linkage, a promoter for driving expression of [the] an isolated nucleic acid fragment [according to any of claims 1-19] which encodes a polypeptide fragment which exhibits a substantial immunological reactivity with a rabbit polyclonal antibody raised against a polypeptide having an apparent molecular weight of 13kDa as determined by SDS-PAGE followed by visualization, said polypeptide being derived from Borrelia burgdorferi B313 and being encoded by the nucleotide sequence of SEQ ID NO: 18, said rabbit polyclonal antibody exhibiting substantially no immunological reactivity with proteins from at least 95% of spirochaetes randomly selected from the group consisting of Borrelia hermsii, Borrelia crocidurae, Borrelia anserina and Borrelia hispanica, and/or hybridises readily under highly stringent hybridization conditions with a DNA fragment having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, or with a DNA fragment complementary thereto, but exhibits no substantial hybridization when the hybridization conditions are highly stringent with genomic DNA from at least 95% of spirochaetes randomly selected from the group consisting of Borrelia hermsii, Borrelia crocidurae, Borrelia anserina and Borrelia hispanica, a nucleic acid sequence encoding a leader peptide enabling secretion of or integration into the membrane of the polypeptide

fragment, [the nucleic acid fragment according to any of claims 1-19,] said isolated nucleic acid fragment, and a nucleic acid sequence encoding a terminator.

Claim 42, line 1: please delete “or 41”.

Please amend Claim 43 as follows:

43. A transformed cell carrying the vector of [any of claims 36-42] claim 36 and capable of replicating [the nucleic acid fragment according to any of claims 1-19] an isolated nucleic acid fragment which encodes a polypeptide fragment which exhibits a substantial immunological reactivity with a rabbit polyclonal antibody raised against a polypeptide having an apparent molecular weight of 13kDa as determined by SDS-PAGE followed by visualization, said polypeptide being derived from Borrelia burgdorferi B313 and being encoded by the nucleotide sequence of SEQ ID NO: 18, said rabbit polyclonal antibody exhibiting substantially no immunological reactivity with proteins from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina* and *Borrelia hispanica*, and/or hybridises readily under highly stringent hybridization conditions with a DNA fragment having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, or with a DNA fragment complementary thereto, but exhibits no substantial hybridization when the hybridization conditions are highly stringent with genomic DNA from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina* and *Borrelia hispanica*.

Please amend Claim 47 as follows:

47. A stable cell line producing [the polypeptide according to any of claims 20-35] a polypeptide fragment which exhibits a substantial immunological reactivity with a

[illegible]

48. A method of preparing a polypeptide fragment [as defined in any of claims 1-19] which exhibits a substantial immunological reactivity with a rabbit polyclonal antibody raised against a polypeptide having an apparent molecular weight of 13kDa as determined by SDS-PAGE followed by visualization, said polypeptide being derived from *Borrelia burgdorferi* B313 and being encoded by the nucleotide sequence of SEQ ID NO: 18, said rabbit polyclonal antibody exhibiting substantially no immunological reactivity with proteins from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina* and *Borrelia hispanica*, and/or hybridises readily under highly stringent hybridization conditions with a DNA fragment having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, or with a DNA fragment complementary thereto, but exhibits no substantial hybridization when the hybridization conditions are highly stringent with genomic DNA from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina* and *Borrelia hispanica*, the method comprising

- 6-

Claim 50, line 1: change “any of claims 20-35” to --claim 20--;

Claim 50, line 2: delete “or of the polypeptide fragment prepared by the method according to claim 48 or 49”;

Claim 52, line 1: delete “or 51”;

Please amend Claim 53 as follows:

53. A live vaccine comprising a non-pathological microorganism carrying and being capable of expressing [the nucleic acid fragment according to any of claims 1-19] an isolated nucleic acid fragment which encodes a polypeptide fragment which exhibits a substantial immunological reactivity with a rabbit polyclonal antibody raised against a polypeptide having an apparent molecular weight of 13kDa as determined by SDS-PAGE followed by visualization, said polypeptide being derived from *Borrelia burgdorferi* B313 and being encoded by the nucleotide sequence of SEQ ID NO: 18, said rabbit polyclonal antibody exhibiting substantially no immunological reactivity with proteins from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina* and *Borrelia hispanica*, and/or hybridises readily under highly stringent hybridization conditions with a DNA fragment having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, or with a DNA fragment complementary thereto, but exhibits no substantial hybridization when the hybridization conditions are highly stringent with genomic DNA from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina* and *Borrelia hispanica* so as to produce the polypeptide fragment according to [any of claims 20-35] claim 20, the live vaccine being effective in conferring

increased resistance to infection with *Borrelia burgdorferi sensu lato* in an animal, including a human being.

Claim 55, line 2: change “any of claims 20-35” to --claim 20--;

Claim 55, line 3: delete “or of the polypeptide fragment prepared by the method according to claim 48 or 49”;

Claim 57, line 2: change “any of claims 20-35” to --claim 20--;

Claim 57, line 2: delete “or at least two non-identical polypeptide fragments prepared by the method according to claim 48 or 49”;

Please amend Claim 58 as follows:

58. A vaccine comprising [the nucleic acid fragment according to any of claims 1-19] an isolated nucleic acid fragment which encodes a polypeptide fragment which exhibits a substantial immunological reactivity with a rabbit polyclonal antibody raised against a polypeptide having an apparent molecular weight of 13kDa as determined by SDS-PAGE followed by visualization, said polypeptide being derived from *Borrelia burgdorferi* B313 and being encoded by the nucleotide sequence of SEQ ID NO: 18, said rabbit polyclonal antibody exhibiting substantially no immunological reactivity with proteins from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina* and *Borrelia hispanica*, and/or hybridises readily under highly stringent hybridization conditions with a DNA fragment having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, or with a DNA fragment complementary thereto, but exhibits no substantial hybridization when the hybridization conditions are highly stringent with genomic DNA from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia*

erp3333

polypeptide being derived from *Borrelia burgdorferi* B313 and being encoded by the nucleotide sequence of SEQ ID NO: 18, said rabbit polyclonal antibody exhibiting substantially no immunological reactivity with proteins from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina* and *Borrelia hispanica*, and/or hybridises readily under highly stringent hybridization conditions with a DNA fragment having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, or with a DNA fragment complementary thereto, but exhibits no substantial hybridization when the hybridization conditions are highly stringent with genomic DNA from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina* and *Borrelia hispanica* and a means for detecting the binding between the nucleic acid fragment and a nucleic acid bound thereto, or

- a set of nucleic acid primers which, when used in a molecular amplification procedure together with the nucleic acid fragment [according to any of claims 1-19], will result in specific amplification of said nucleic acid fragment, and a means for detecting the amplified nucleic acid fragment.

Claim 66, line 3: change “any of claims 20-35” to --claim 20--; and

Claim 66, line 3: delete “or prepared according to the method of claim 48 or 49”.

Please add the following claims:

--67. A vaccine comprising an amount of the polypeptide fragment prepared by the method according to claim 48, the amount of the polypeptide fragment being effective to confer substantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in an animal, including a human being, the polypeptide fragment being formulated in combination



with a pharmaceutically acceptable carrier, diluent or vehicle, and the vaccine optionally further comprising an adjuvant.

68. A combination vaccine comprising an amount of the polypeptide fragment prepared according to the method of claim 48, the amount of the polypeptide fragment being effective to confer substantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in an animal, including a human being; and at least one further Borrelia antigen, the polypeptide fragment and the antigen being formulated in combination with a pharmaceutically acceptable carrier, vehicle or diluent and the vaccine optionally further comprising an adjuvant.

69. A combination vaccine comprising at least two non-identical polypeptide fragments prepared by the method according to claim 48, the vaccine comprising an amount of the polypeptide fragments effective to confer substantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in a animal, including a human being, in combination with a pharmaceutically acceptable carrier, vehicle, or diluent, the vaccine optionally further comprising an adjuvant.

70. A diagnostic composition adapted for the determination of *Borrelia burgdorferi sensu lato* in a sample, the composition comprising the polypeptide fragment prepared by the method according to claim 48, the amount of the polypeptide fragment being effective to detectably react with antibodies present in the sample, the antibodies being directed against *Borrelia burgdorferi sensu lato*, the composition optionally comprising a detectable label.

71. A method of determining the presence of antibodies directed against *Borrelia burgdorferi sensu lato* in a sample, comprising incubating the sample with the

72. A method for the preparation of an immunological composition such as a vaccine, the method comprising the steps of admixing a polypeptide fragment prepared according to the method of claim 48, a pharmaceutically acceptable carrier, vehicle, or diluent, and optionally an adjuvant.--

This application includes multiple claim dependencies. The amendment reduces the multiple claim dependencies, and the filing fee for this application was computed on this basis. No estoppel, surrender of subject matter, waiver, admission, or prejudice is intended by this amendment.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG/LLP

FROMMER LAWRENCE & HAUGLI  
Thomas J. Kunk

Thomas J. Kowalski  
Reg. No. 32,147  
(212) 588-0800

P13 antigens from *Borrelia*

## FIELD OF THE INVENTION

5 The present invention relates to nucleic acid sequences encoding antigenic proteins associated with *Borrelia burgdorferi sensu lato* (*Borrelia burgdorferi sensu stricto*, *Borrelia garinii*, and *Borrelia afzelii*; collectively designated Bb hereinafter), particularly polypeptides associated with virulence; vaccine formulations comprising these polypeptides are also part of the invention. The invention also relates to methods for pro-

10 ducing Bb immunogenic polypeptides and corresponding antibodies. Other embodiments of the invention relate to methods for detecting Lyme disease and transformed cells comprising Bb associated nucleic acids.

## BACKGROUND OF THE INVENTION

15

Lyme disease is a multisystem disease resulting from tick transmission of the infectious agent, Bb (Rahn and Malawista, 1991). Although recognised as a clinical entity within the last few decades (Steere et al., 1977), case reports resembling Lyme disease date back to the early part of the 20th century. Cases of the disease

20 have been reported in Europe, Asia and North America (Schmid, 1985). Despite a relatively low total incidence compared to other infectious diseases, Lyme disease represents a significant health problem because of its potentially severe cardiovascular, neurologic and arthritic complications, difficulty in diagnosis and treatment and high prevalence in some geographic regions.

25

Bb is not a homogeneous group but has a variable genetic content, which may in turn affect its virulence, pattern of pathogenesis and immunogenicity. Lyme borreliosis associated borreliae are so far taxonomically placed into three species, *Borrelia burgdorferi sensu stricto*, *Borrelia garinii*, and *Borrelia afzelii* (Burgdorfer et al., 1983,

30 Baranton et al., 1992, Canica et al., 1993). It is well documented that considerable genetic, antigenic and immunogenic heterogeneity occurs among them, as well as among the strains within the separate species (Baranton et al., 1992, Canica et al., 1993, Zingg et al., 1993, Wilske et al., 1993, Adam et al., 1991, Marconi and Garon 1992). The major evidence of this phenomenon is provided by the molecular studies

35 of the plasmid-encoded outer surface protein A (OspA), OspB and OspC (Barbour et al., 1984, Jonsson et al., 1992, Wilske et al., 1993, Marconi et al., 1993). In different animal models efficient protection is achieved by passive and active immunisation with OspA (Schaible et al., 1990, Fikrig et al., 1992, Erdile et al., 1993), and therefore, OspA remains one of the main candidates for *Borrelia* vaccine. It is unclear,

however, whether inter- and intra-species heterogeneity of OspA, as well as other competitors for immunoprophylaxis, allow efficient cross-protection (Fikrig et al., 1992, Norris et al., 1992). Furthermore, it was recently suggested that certain protective antibodies produced early in the course of *Borrelia* infection are unrelated to  
5 OspA (Norton Hughes et al., 1993, Barthold and Bockenstedt, 1993).

Its virulence factors, pathogenetic mechanisms and means of immune evasion are unknown. At the level of patient care, diagnosis of the disease is complicated by its varied clinical presentation and the lack of practical, standardised diagnostic tests of  
10 high sensitivity and specificity. Antimicrobial therapy is not always effective, particularly in the later stages of the disease.

Variation among Bb strains and species and the changes resulting from *in vitro* passage add to the problems of developing vaccines or immunodiagnostics from either  
15 the whole organism or specifically associated proteins. Using a PCR assay, it was found that one set of oligonucleotide primers was specific for North American Bb isolates, another for most European isolates and a third set recognised all Bb strains (Rosa et al., 1989).

20 Serological assays for the diagnosis and detection of Lyme disease are thought to offer the best promise for sensitive and specific diagnosis. However, serologic assays generally use whole Bb as antigen and suffer from a low "signal to noise" ratio, i.e., a low degree of reactivity in positive samples, particularly early in the disease, as compared to negative samples. This problem results in high numbers of false negatives  
25 and the potential for false positives. Background reactivity in negative controls may be due in part to conserved antigens such as the 41K flagellin and the 60K "Common Antigen". These Bb proteins possess a high degree of sequence homology with similar proteins found in other bacteria. Therefore normal individuals will often express anti-flagellar and anti-60K antibodies. Unique, highly reactive Bb antigens for  
30 serological assays are therefore desirable but heretofore unavailable.

Diagnosis of Lyme disease remains a complex and uncertain endeavour, due to lack of any single diagnostic tool that is both sensitive and specific. Clinical manifestations and history are the most common bases for diagnosis. However, there is a  
35 pressing need for specific, sensitive, reproducible and readily available confirmatory tests. Direct detection offers proof of infection but is hampered by the extremely low levels of Bb that are typically present during infection, as well as the inaccessibility of sites that tend to be consistently positive (e.g., heart and bladder). Culture, although sensitive, is cumbersome and requires 1-3 weeks to obtain a positive result. PCR

appears to offer promise in terms of direct detection (Lebech et al., 1991) and indeed Goodman et al. (1991) have reported detection of Bb DNA in the urine of patients with active Lyme disease using a PCR method. However, it is unlikely that PCR assays will become commonly used in clinical laboratories because of the degree of skill required for its use and the high risk of DNA contamination.

Another problem in detection of Lyme disease is the substantial number of humans exposed to Bb who develop inapparent or asymptomatic infections. This number has been estimated to be as high as 50% (Steere et al., 1986).

10

There is clearly a need for means of preparing Bb-specific antigens, e.g., for the development of diagnostic tests for Lyme disease. Adequate assays do not exist and should ideally meet several criteria, including (1) expression of an antigen by all pathogenic Bb strains, (2) elicitation of an immune response in all Lyme disease patients, (3) high immunogenicity with a detectable antibody response early in the infection stage, (4) antigens unique to Bb without cross-reactivity to other antigens, and (5) distinction between individuals exposed to non-pathogenic as opposed to pathogenic forms of Bb.

20 There have been several studies describing low molecular weight proteins from Bb. Katona et al. showed the presence of a major low-molecular weight lipoprotein specific for *B. burgdorferi* and raised the possibility that it was a borrelial equivalent of Braun's lipoprotein (Katona et al., 1992). Another study reported an immunogenic 14 kDa surface protein of *B. burgdorferi* recognised by sera from Lyme disease patients (Sambri et al., 1991). A 14 kDa mitogenic lipoprotein of *B. burgdorferi* was reported by Honarvar et al. (1994).

Sadziene et al. (1994) when analysing an Osp-less *B. burgdorferi* strain identified a 13 kDa surface exposed protein which was designated p13.

30

#### OBJECT OF THE INVENTION

It is an object of the invention to provide novel nucleic acid fragments and polypeptide fragments which are useful in the preparation of diagnostics and prophylactic means and compositions relating to infections with Bb. It is a further object to provide novel vaccines and diagnostic means as well as methods for the preparation and use of such vaccines and diagnostic means. Finally, it is an object of the invention to

provide tools such as vectors and transformed cells which facilitate the preparation of the polypeptide fragments and the vaccines.

## 5 SUMMARY OF THE INVENTION

The inventors have surprisingly found that an antigen from Bb with an apparent molecular weight of 13 kDa (determined by SDS-PAGE, and subsequent visualization such as staining with Coomassie Blue) is highly conserved in the three strains *B. burgdor-*  
10 *feri sensu stricto* B31, *B. garinii* IP90, and *B. afzelii* ACAI, whereas this antigen cannot be found in *Borrelia* species related to relapsing fever and avian borreliosis. The disclosed antigens are therefore excellent candidates for vaccines and diagnostics relating to infections with Bb. The antigens will be termed P13.

15 The present invention thus addresses one or more of the foregoing or other problems associated with the preparation and use of Bb specific antigens, particularly those antigens associated with virulence and which are useful for developing detection and diagnostic methods for Lyme disease. The present invention involves the identifica-  
20 tion of such antigens, which herein are designated P13 as well as the identification and isolation of Bb nucleic acid sequences that encode P13 antigens or antigenic polypeptides derived therefrom. These sequences are useful for preparing expression vectors for transforming host cells to produce recombinant antigenic polypeptides. It is further proposed that these antigens will be useful as vaccines or immunodiag-  
25 nostic agents for Bb associated diseases such as Lyme disease in particular.

25

The DNA of the present invention was isolated from Bb. The microorganism is a spiral-shaped organism approximately 0.2 micron in diameter and ranging in length from about 10 to 30 microns. Like other spirochaetes, it possesses an inner membrane, a thin peptidoglycan layer, an outer membrane, and periplasmic flagella which  
30 lie between the inner and outer membranes. Bb is an obligate parasite found only in association with infected animals and arthropod vectors in endemic areas. Bb-like organisms have also been identified in birds raising the possibility that birds could also serve as an animal reservoir. While some Bb isolates have been cloned, most isolates have not been cloned and most likely represent mixtures of different variants  
35 even at the time of culture origin.

Bb has similarities with other relapsing fever organisms such as *B. hermsii*. Bb has a single chromosome with two unusual features, linear conformation and small size (approximately 900 kilobase pairs). Fresh isolates of Bb contain up to four linear

plasmids and six circular supercoiled plasmids. The plasmid content of different Bb isolates is highly variable. For example, in one study only two of thirteen strains had similar plasmid profiles. Some plasmids are lost during *in vitro* passage which may correlate with loss of virulence. Outer surface proteins OspA and OspB are encoded on the 49 kbp linear plasmid. The P13 membrane-associated/outer surface proteins discovered by the inventors are encoded on the Bb chromosome. The P13 protein gene being localised to the chromosome of borreliae shows a higher degree of conservation among Lyme disease associated borreliae contrary to the plasmid-encoded major outer surface proteins A, B, and C which exhibit a significant species and strain dependent genetic and antigenic polymorphism (Barbour 1986, Jonsson et al., 1992, Wilske et al., 1993). Furthermore, the level of similarity and identity between the deduced amino acid sequence of the P13 protein from different borrelia strains further shows that this protein can be useful as a vaccine against Lyme disease as well as a target for diagnostic use.

15

In order to identify DNA segments encoding the P13 proteins, purified protein was isolated from *B. burgdorferi* B313 by preparative SDS-PAGE for subsequent use in amino acid sequencing. Attempts to N-terminally sequence the purified protein by standard techniques were unsuccessful. The protein was therefore subjected to V8 protease cleavage. After protease cleavage the peptide was transferred to poly-vinylene diffusable membranes, and sequence analysis was performed using standard sequencing techniques (Matsudaira, 1987). A 25 amino acid sequence was identified (SEQ ID NO: 1).

25 DNA libraries were prepared by restriction enzyme digestion of DNA prepared from the strains *B. burgdorferi* B31, *B. afzelii* ACA1 and *B. garinii* IP90.

Codons for the amino acid sequence obtained, SEQ ID NO: 1, were selected by reverse translation based on (1) conclusion that codons containing A or T were favoured and (2) knowledge of published DNA sequences for several Bb proteins. A choice favouring A or T containing codons was based on the observation that the G + C content of Bb is only 28-35% (Burman et al., 1990). Two oligonucleotides were synthesized having the sequences shown in in SEQ ID NO: 2 and SEQ ID NO:3.

These were used as primers in a PCR reaction with DNA prepared from *B. burgdorferi* B31 as template. The amplified fragment was sequenced, SEQ ID NO: 4, and verified to code for the amino acid sequence, SEQ ID NO: 1.

A DNA probe, designated Y7 (SEQ ID NO:7), was designed and used to screen the DNA library prepared from *B. burgdorferi* B31 in an attempt to identify DNA encoding the P13 protein from this Bb species. This attempt proved unsuccessful.

- 5 An *RsaI* restriction site identified in the DNA sequence of the PCR fragment was used in a further attempt to clone the P13 gene. Bb DNA was digested with *RsaI* and the fragments cloned into a pUC plasmid. Further PCR amplification using the sequence identified surrounding the *RsaI* site yielded DNA fragments which were found to code for the P13 protein.

10

The identified sequence of the P13 gene from *B. burgdorferi* B31 was used to design PCR primers which were subsequently used to clone the P13 gene from *B. afzelii* ACAI and *B. garinii* IP90.

- 15 The P13 protein which has been cloned by the inventors of the present invention has been shown to have a molecular weight of about 19,000 as calculated from the deduced amino acid sequence of the full-length protein but a molecular weight of about 14,000 as determined by MS but nevertheless to be identical to a protein from Bb which has an apparent molecular weight in SDS-PAGE of 13 kDa. This difference  
20 can be explained by post-translational modifications of the P13 protein. This is in accordance with the observation that it was not possible by standard methods to obtain an N-terminal amino acid sequence of P13 protein prepared from Bb.

The deduced amino acid sequences of P13 from *B. burgdorferi* B31, *B. afzelii* ACAI  
25 and *B. garinii* IP90 were analysed and it was found that the N-terminal regions of the deduced amino acid sequences are typical of the signal peptides of bacterial proteins. These leader peptide sequences are typical of exported proteins with a basic residue followed by a hydrophobic and a potential leader peptidase I cleavage site according to the criteria established by von Heijne (1986).

30

Amino acid sequences resembling the signal sequences of bacterial lipoproteins can also be found in the N-terminal region of the deduced amino acid sequences. The N-terminal methionine is followed by a hydrophobic region and a signal peptidase II recognition sequence. The signal sequences, Leu Ala Thr Phe Cys for *B. burgdorferi*  
35 B31, Leu Leu Ala Phe Cys for *B. afzelii* ACAI and Leu Val Ile Phe Cys for *B. garinii* IP90, differed somewhat from the consensus signal peptidase II recognition sequence (Leu Xaa Xaa Cys) found in most bacteria, but resembled the cleavage sequence Leu Ser Ile Ser Cys of the outer surface protein D (OspD) of Bb and Leu Met Ile Gly Cys of the variable major proteins Vmp7 and Vmp21 of *B. hermsii*. These surface anti-



gens have been shown to be lipoproteins (Norris et al., 1992; Burman et al., 1990). The presence of this leader sequence may imply that mature P13 proteins are translocated across the cytoplasmic membrane and are anchored to the cytoplasmic membrane and/or outer membranes via fatty acids associated with an N-terminal cysteinyl  
5 residue. Lipidated forms of the outer surface protein A (OspA) from Bb have been shown to be more immunogenic than non-lipidated forms of OspA (Erdile et al., 1993).

However, it should be understood that when the terms "13 kDa protein" or "13 kDa  
10 antigen" or "13 kDa polypeptide" are used in the present specification and claims, this is an alternative designation of the P13 polypeptide.

Antigenicity of the P13 protein was verified by immunisation of a rabbit. Antiserum collected from rabbits injected with the P13 protein prepared from *B. burgdorferi*  
15 B313 was found to recognise the P13 protein of *B. burgdorferi* B31, *B. afzelii* ACA1, and *B. garinii* IP90. There was no apparent reactivity of the antiserum with *B. hermsii*, *B. crocidurae*, *B. anserina*.

The nucleic acid segments of the present invention encode antigenic amino acid  
20 sequences associated with Bb. These sequences are important for their ability to selectively hybridise with complementary stretches of Bb gene segments. Varying conditions of hybridization may be desired, depending on the application envisioned and the selectivity of the probe toward the target sequence. Where a high degree of selectivity is desired, one may employ relatively stringent conditions to form the  
25 hybrids, such as relatively low salt and/or high temperature conditions. Under these conditions, little mismatch between the probe and template or target strand is tolerated. Less stringent conditions might be employed when, for example, one desires to prepare mutants or to detect mutants when significant divergence exists.

30 In clinical diagnostic embodiments, nucleic acid segments of the present invention may be used in combination with an appropriate means, such as a label, to determine hybridization with DNA of a pathogenic organism. Typical methods of detection might utilise, for example, radioactive species, enzyme-active or other marker ligands such as avidin/biotin, which are detectable directly or indirectly. In preferred diagnostic  
35 embodiments, one will likely desire to employ an enzyme tag such as alkaline phosphatase or peroxidase rather than radioactive or other reagents that may have undesirable environmental effects. Enzyme tags, for example, often utilise colorimetric indicator substrates that are readily detectable spectrophotometrically, many in the

visible wavelength range. Luminescent substrates could also be used for increased sensitivity.

Hybridisable DNA segments may include any of a number of segments of the dis-  
5 closed DNA. For example, relatively short segments of at least 12 or so base pairs  
may be employed, or, more preferably when probes are desired, longer segments of  
at least 20, at least 30, and at least 40 base pairs, depending on the particular  
applications desired. Shorter segments are preferred as primers in molecular amplifi-  
10 cation techniques such as PCR, while some of the longer segments are generally  
preferable for blot hybridizations. It should be pointed out, however, that while  
sequences disclosed for the DNA segments of the present invention are defined by  
SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22, a certain amount of variation or  
base substitution would be expected, e.g., as may be found in mutants or strain  
15 variations, including base modifications occurring naturally or otherwise, are intended  
to be included within the scope of the present invention.

While the Bb P13 antigens of the present invention have been disclosed in terms of  
the specific amino acid sequences SEQ ID NO: 19, SEQ ID NO: 21 and SEQ ID NO:  
20 23, it is nonetheless contemplated that the amino acid sequences will be found to  
vary from species to species and from isolate to isolate. Moreover, it is quite clear  
that changes may be made in the underlying amino acid sequence through, e.g., site-  
directed mutagenesis of the DNA coding sequence, in a way that will not negate its  
antigenic capability.

25

The invention also relates to at least partially purified antigenic Bb proteins or poly-  
peptides which are capable of producing an *in vivo* immunogenic response when  
challenged with Bb. These proteins may comprise all or part of the amino acid se-  
quence encoded by the DNA disclosed herein. Particularly preferred antigenic proteins  
30 have the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 21 and SEQ ID  
NO: 23. Post-translationally modified forms of these antigenic proteins are also the  
subject of this invention. These proteins as well as their epitopes will be useful in  
connection with vaccine development, and as antigen(s) in immunoassays for detec-  
tion of Bb antibodies in biological fluids such as serum, seminal or vaginal fluids,  
35 urine, saliva, body exudates and the like.

In other aspects, the invention concerns recombinant vectors such as plasmids,  
phages or viruses, which comprise DNA segments in accordance with the invention,  
for use in replicating such sequences or even for the expression of encoded antigenic

peptides or proteins. Vectors or plasmids may be used to transform a selected host cell. In preparing a suitable vector for transforming a cell, desired DNA segments from any of several Bb sources may be used, including genomic fragments, cDNA or synthetic DNA. In the practice of the present invention, an expression vector may

5 incorporate at least part of the DNA sequence of SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22, encoding one or more epitopic segments of the disclosed antigens of the present invention.

Expression vectors may be constructed to include any of the DNA segments herein-

10 above disclosed. Such DNA might encode an antigenic protein specific for virulent strains of Bb or even hybridization probes for detecting Bb nucleic acids in samples. Longer or shorter DNA segments could be used, depending on the antigenic protein desired. Epitopic regions of the disclosed proteins of the present invention expressed or encoded by the disclosed DNA could be included as relatively short segments of

15 DNA. A wide variety of expression vectors are possible including, for example, DNA segments encoding reporter gene products useful for identification of heterologous gene products and/or resistance genes such as antibiotic resistance genes which may be useful in identifying transformed cells.

20 Recombinant vectors such as those described are particularly preferred for transforming bacterial host cells. Accordingly, a method is disclosed for preparing transformed bacterial host cells that generally includes the steps of selecting a suitable bacterial host cell, preparing a vector containing a desired DNA segment and transforming the selected bacterial host cell. Several types of bacterial host cells may be employed,

25 including Bb, *E. coli*, *B. subtilis*, and the like as well as prokaryotic host cells.

Transformed cells may be selected using various techniques, including screening by differential hybridization, differential display techniques, identification of fused reporter gene products, resistance markers, anti-antigen antibodies and the like. After

30 identification of an appropriate clone, it may be selected and cultivated under conditions appropriate to the circumstances, as for example, conditions favouring expression or, when DNA is desired, replication conditions.

Another aspect of the invention involves the preparation of antibodies and vaccines

35 from the antigenic P13 proteins or epitopic regions of these proteins encoded by the disclosed DNA. It is expected that the sensitivity and specificity of an antibody response to these P13 proteins and their epitopes will be superior to the response that has been obtained from other Bb antigens that are not associated with virulence. Previous work with several Bb antigens isolated from both virulent and avirulent

strains indicated low sensitivity when immunofluorescence and ELISA assays were employed, especially during early stages of infection.

In both immunodiagnostics and vaccine preparation, it is often possible and indeed more practical to prepare antigens from segments of a known immunogenic protein or polypeptide. Certain epitopic regions may be used to produce responses similar to those produced by the entire antigenic polypeptide. Potential antigenic or immunogenic regions may be identified by any of a number of approaches, e.g., Jameson-Wolf or Kyte-Doolittle antigenicity analyses or Hopp and Woods (1981) hydrophobicity analysis (see, e.g., Kyte and Doolittle, 1982, or U.S. Patent No. 4,554,101). Hydrophobicity analysis assigns average hydrophilicity values to each amino acid residue, and from these values average hydrophilicities can be calculated and regions of greatest hydrophilicity determined. Using one or more of these methods, regions of predicted antigenicity may be derived from the amino acid sequence of the disclosed P13 polypeptides. Proposed epitopic regions from the disclosed P13 antigens include the sequences corresponding to amino acid residues 7-15, 21-24, 29-35, 83-92, 126-135 and 162-167 in SEQ ID NO: 19; amino acid residues 7-14, 20-23, 28-35, 82-89, 125-134 and 162-166 in SEQ ID NO: 21; and amino acid residues 6-14, 18-21, 27-34, 79-92, 125-133 and 161-165 in SEQ ID NO: 23.

20

Antigenic epitopes can also be determined using different experimental procedures known to the skilled person. For example, the DNA encoding the P13 polypeptides can be digested with restriction enzymes in such a manner that DNA fragments encoding specific parts of the P13 polypeptide are obtained. These DNA fragments can be expressed in a suitable expression system. The P13 polypeptide fragments obtained can be analysed with monoclonal or polyclonal antibodies obtained by immunisation with the full-length form of the P13 polypeptide or fragments thereof, or with Lyme disease patient sera to obtain information about immunogenicity and the presence of epitopes. Fragments found to be positive in such a simple screening assay where they react specifically with e.g. polyclonals raised against P13 are thus suitable candidates for a multitude of the applications where full-length P13 would also be suitable.

A similar approach can be used where random mutations are introduced in the nucleotide sequence encoding P13, and only the expression products which retain a suitable reactivity with e.g. P13 positive polyclonal antibodies will be used as candidates for further applications.

Peptide fragments for the identification of epitopes can also be obtained by synthetic methods. Suitable peptides can be synthesised based on the amino acid sequence of the P13 polypeptides, e.g. peptides with amino acid sequences identical to consecutive fragments from the N-terminus to the C-terminus of the P13 polypeptide can be synthesised on solid-phase media. Such custom-made peptide libraries can be obtained from commercial sources.

Finally, another way of simply identifying epitopes is to digest a polypeptide antigen with a known amino acid sequence with endo- and exopeptidases. The obtained fragments are tested against antibodies directed against the whole polypeptide, and by way of deduction, the precise location of the linear epitopes can be determined. A variation of this method involves the recombinant production of subfragments (cf. the above) of the full-length polypeptide followed by the same test procedure.

It is contemplated that the antigens and immunogens of the invention will be useful in providing the basis for one or more assays to detect antibodies against Bb. Previous assays have used whole Bb as the antigen. Sera from normal individuals not exposed to Bb often contain antibodies that react with Bb antigens, in particular antigens that have epitopes in common with other bacteria. It is necessary to adjust assay conditions or the diagnostic threshold of reactivity to avoid false positive reactions due to these cross-reactive antibodies in normal sera. These adjustments may in turn decrease the sensitivity of the assay and lead to false negative reactions, particularly in the early stages of Bb infection. Assays using the disclosed P13 proteins or antigenic polypeptides thereof are expected to give superior results both in terms of sensitivity and selectivity when compared to assays that use whole Bb or even purified flagella in either an indirect ELISA or an antibody capture ELISA format. Western immunoblots based on reactions with such antigens (whole Bb, flagella and the like) have been difficult to interpret due to the presence of antibodies in sera from unexposed individuals. These antibodies cross-react with Bb antigens, most particularly the 41 kDa flagellin and the 60 kDa common antigen protein. Generally, assays which use whole organisms or purified flagella tend to contain antigens with epitopes that will cross-react with other bacterial antigens. For example, the N and C terminal regions of the Bb flagellin possess 52-55% sequence identity with the *Salmonella typhimurium* and *Bacillus subtilis* sequences (Wallich et al., 1990), exemplifying the highly conserved nature of flagellin structure. The 60 kDa Bb protein is likewise 58% homologous with the *E. coli* protein (Shanafelt et al., 1991). Such cross-reactivity is not likely with the disclosed P13 antigens, which are apparently unique to Bb.

It is further anticipated that recombinantly derived P13 Bb proteins will be particularly preferred for detecting Bb infections. Unexposed individuals should have a low reactivity to one or more epitopes of the P13 proteins thereby making it possible to use lower dilutions of serum and increase sensitivity. Using a combination of more than one of these unique antigens may also enhance sensitivity without sacrificing specificity.

Preferred immunoassays are contemplated as including various types of enzyme linked immunoassays (ELISAs), immunoblot techniques, and the like, known in the art. However, it is readily appreciated that utility is not limited to such assays, and useful embodiments include RIAs and other non-enzyme linked antibody binding assays or procedures.

Yet another aspect of the invention is a method of detecting Bb nucleic acid in a sample. The presence of Bb nucleic acid in the sample may be indicated by the presence of the polypeptide products which it encodes. The method therefore includes detecting the presence of at least a portion of any of the polypeptides herein disclosed. Suitable detection methods include, for example, immunodetection reagents, PCR amplification, and hybridization.

Yet another aspect of the invention includes one or more primers capable of priming amplification of the disclosed DNA of SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22. Such primers are readily generated taking into account the base sequence of the DNA segment of SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22, the disclosed DNA, or deriving a base sequence from the amino acid sequence of a purified polypeptide encoded by the DNA. Primers are analogous to hybridization probes, but are generally relatively short DNA segments, usually about 7-20 nucleotides.

Methods of diagnosing Lyme disease are also included in the invention. In one embodiment, an antibody-based method includes obtaining a sample from a patient suspected of having Lyme disease, exposing that sample to one or more epitopes of the Bb protein which is encoded by the DNA disclosed, and finally determining a reactivity of the antibody with one or more epitopes of a Bb protein that may be in the sample. The reactivity measured is indicative of the presence of Lyme disease. Typical samples obtainable from a patient include human serum, plasma, whole blood, cerebrospinal fluid, seminal or vaginal fluids, exudates and the like.

Several variations of antibody-based methods are contemplated for development; for example, an indirect ELISA using the P13 proteins or other Bb proteins as an antigen.

The P13 proteins may be produced in large quantities by recombinant DNA vectors already disclosed and purified. Optimum concentration of the antigen could be determined by checker board titration and diagnostic potential of the P13 proteins assay examined further by testing serum from mice at different stages of infection and  
5 infected with different strains of Bb. These results could indicate the relative time course for serum conversion for each of the assays and would also show whether infection with different strains causes variation in anti-P13 protein titers.

Likewise, reactive epitopes of the P13 polypeptides are contemplated as useful either  
10 as antigens in an ELISA assay or to inhibit the reaction of antibodies toward intact P13 proteins bound to a well. Epitopic peptides could be generated by recombinant DNA techniques previously disclosed or by synthesis of peptides from individual amino acids. In either case, reaction with a given peptide would indicate presence of antibodies directed against one or more epitopes. In addition to its diagnostic poten-  
15 tial, this method is seen as being particularly effective in characterising monoclonal antibodies against the P13 proteins and other virulence associated proteins.

In a further aspect, the present invention concerns a kit for the detection of Bb anti-  
gens, the kit including a protein or peptide which includes an epitope thereof, to-  
20 gether with means for detecting a specific immunoreaction between an antibody and its corresponding antigen. Examples of suitable means include labels attached directly to the antigen or antibody, a secondary antibody having specificity for human Ig, or protein A or protein G. Alternatively, avidin-biotin mediated *Staphylococcus aureus* binding could be used. For example, the monoclonal antibody may be biotinylated so  
25 as to react with avidin complexed with an enzyme or a fluorescent compound.

A particular kit embodiment of the invention concerns detection of antibodies against the described Bb P13 antigens, epitopes thereof as represented by portions of the amino acid sequences, or closely related proteins or peptides, such as epitopes asso-  
30 ciated with other virulence-associated proteins detected by comparison of low-passage, virulent and high-passage, avirulent strains of Bb. The antigen for the kit(s) consists of the Bb P13 proteins or portions thereof produced by a recombinant DNA vector in *E. coli* or another bacterial or non-bacterial host. Alternatively, the antigen may be purified directly from Bb or manufactured as a synthetic peptide. Samples for  
35 the assays may be body fluids or other tissue samples from humans or animals. The presence of reactive antibodies in the samples may be demonstrated by antibody binding to antigen followed by detection of the antibody-antigen complex by any of a number of methods, including ELISA, TRIFMA (time-resolved immunofluorometric assay), RIA, fluorescence, agglutination or precipitation reactions, nephelometry, or

5 of therapy

10 between such a probe and Bb nucleic acid, such as an associated label.

### LEGENDS TO THE FIGURES

- 15 Figure 1A, 1B and 1C. Analysis of *Borrelia* proteins.
- A: Effect of Protease K treatment on Bb cells. Coomassie-blue stained 15% SDS-PAGE gel showing protein profiles of whole cell (WC), B-fraction (BF) and Proteinase K (PK) treated cells from *B. burgdorferi* B31, *B. afzelii* ACA1 and *B. garinii* IP90.
- B: The Western Blot corresponding to Figure 1A probed with the rabbit polyclonal antiserum raised against the 13 kDa protein prepared from *B. burgdorferi* B313.
- C: Comparison of phenotypic expression of the 13 kDa protein in *Borrelia* species. Western Blot of SDS-PAGE separated proteins from *B. hermsii* and *B. crocidurae* probed with the rabbit polyclonal antiserum raised against the 13 kDa protein prepared from *B. burgdorferi* B313.
- 25 Arrows indicate the position of 13 kDa protein. Mw - molecular weight standard, kD - kilodalton.

Figure 2A and 2B. Demonstration of outer membrane association of the 13 kDa protein.

- 30 A: Electron micrographs of immunogold-stained cells from *B. burgdorferi* B31.  
B: Electron micrographs of immunogold-stained cells from *B. burgdorferi* B313.  
Monoclonal antibody 15G6 was used as the primary antibody.

Figure 3A and 3B. Analysis of membrane Fraction B.

- 35 A: Coomassie-blue stained 15% SDS-PAGE gel showing protein profiles of Fraction B (BF) prepared from cells from *B. burgdorferi* B31, *B. afzelii* ACA1 and *B. garinii* IP90. B: The corresponding Western Blot probed with the monoclonal antibody 15G6. Arrows indicate the position of 13 kDa protein. Mw - molecular weight standard, kD - kilodalton.



2

100

**Wiley**

511

11

and

Figure 9. Electron mass spectrum of purified P13 protein.

The molecular masses of the three major components are indicated above the peaks.

## 5 DETAILED DESCRIPTION OF THE INVENTION

### Nucleic acid fragments of the invention

The present invention relates to the utility of Bb associated nucleic acid fragments as  
10 diagnostic or preventive tools in Lyme disease as well as for the preparation of P13  
and useful P13 analogues.

In a first aspect the present invention therefore relates to an isolated nucleic acid  
fragment encoding a polypeptide fragment which exhibits a substantial immunological  
15 reactivity with a rabbit polyclonal antibody raised against a polypeptide having an  
apparent molecular weight of 13 kDa as determined by SDS-PAGE and subsequent  
visualization, said polypeptide being derived from *Borrelia burgdorferi* B313 and con-  
sisting of the amino acid sequence of SEQ ID NO: 19 or a post-translationally modi-  
fied form thereof, said rabbit polyclonal antibody exhibiting substantially no immuno-  
20 logical reactivity with proteins from at least 95% of spirochaetes randomly selected  
from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*,  
and *Borrelia hispanica*.

By the term "nucleic acid fragment" as used herein is meant a fragment of DNA or  
25 RNA, but also of PNA (cf. Nielsen et al., 1991), having a length of at least two joined  
nucleotides. It will be understood that although the disclosed nucleic acid fragments  
of the present invention are DNA fragments, it may be desirable to employ an RNA  
fragment in e.g. a viral vector, the genome of which is natively composed of RNA.  
For the purposes of preparing e.g. probes for hybridization assays as described  
30 below, PNA fragments may prove useful, as these artificial nucleic acids have been  
demonstrated to exhibit very dynamic hybridization properties.

The term "a substantial immunological reactivity" is meant to designate a marked  
immunological binding between an antibody/antiserum on the one hand, and on the  
35 other hand an antigen, under well-defined conditions with respect to physicochemical  
parameters as well as concentrations of antigens and antibodies. Thus, a substantial  
immunological reactivity should be clearly distinguishable from a non-specific inter-  
action between an antibody/antiserum and an antigen. This distinction can for in-  
stance be made by reacting the antibody/antiserum with a known concentration of an

antigen which has previously been shown not to react with the antibody/antiserum, and then using this reaction as a negative control. A positive control could suitably be the reaction between the antibody/antiserum and the same concentration of the antigen used for the immunisation resulting in the production of the antibody/antiserum.

- 5 In such an assay, an antigen resulting in a relative signal of at least 10% (calculated as  $S_m \cdot (S_p - S_n) \cdot 100$ , where  $S_m$  is the measured signal,  $S_p$  the positive control signal, and  $S_n$  the negative control signal) is regarded as having a substantial immunological reactivity. An antigen exhibiting "substantially no immunological reactivity" is therefore defined as an antigen giving a signal of less than 10%.

10

By the terms "present" and "substantially absent", when referring to amino acid sequences and polypeptides in bacteria, is meant that the concentration of the amino acid sequence/polypeptide in a bacterium where it is "present" is at least 100 times higher than in a bacterium where it is substantially absent. However, it is preferred

- 15 that the ratio of the concentrations are at least 1000, and more preferred at least 10,000, 100,000 or even higher. It is especially preferred that no concentration of the amino acid sequence/polypeptide can be observed in the bacterium from where it is substantially absent.

- 20 Although the data presented herein demonstrate that there is no cross-reactivity between antigens from *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, or *Borrelia hispanica* and the disclosed polypeptides, it is conceivable that a few isolates of these bacteria will exhibit some cross-reactivity. As can be deduced from the above it is expected that the cross-reactivity will be less than 5% (since there is no
- 25 reactivity with at least 95% of randomly chosen *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, or *Borrelia hispanica*), and according to the invention this cross-reactivity may be even lower, such as at the most 4% and 3%, preferably at the most 2%, such as 1%. According to the invention the cross-reactivity is most preferred at most 1/2%, such as 0%. In such a case there will be no substantial
- 30 immunological reactivity between the rabbit antiserum mentioned above and whole cell preparations of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, or *Borrelia hispanica*.

- When using the term "cross-reactivity" is herein meant the phenomenon that two
- 35 species exhibit a common feature which is detected in a reaction. In the present context the term cross-reactivity is used for similar reactions in antigen-antibody interactions as well as in hybridization interactions. Hence, the above-cited considerations concerning cross-reactivity of polypeptides apply for all cross-reactions between on the one hand the polypeptides/DNA fragments of the invention and on

the other hand material from *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*; this is also true for the quantitative assessment of whether cross-reactivity is present or not.

5 Nucleic acid fragments of the invention useful as hybridization probes and/or primers are not necessarily those fragments encoding immunologically useful polypeptides. Therefore the invention also relates to nucleic acid fragments which hybridise readily under highly stringent hybridization conditions with a DNA fragment having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID  
10 NO: 20, and SEQ ID NO: 22, or with a DNA fragment complementary thereto, but exhibit no substantial hybridization when the hybridization conditions are highly stringent with genomic DNA from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*. The term "highly stringent" when used in conjunction with  
15 hybridization conditions is as defined in the art, i.e. 5-10°C under the melting point  $T_m$ , cf. Sambrook et al, 1989, pages 11.45-11.49.

Interesting nucleic acid fragments of the invention encode a polypeptide fragment comprising an amino acid sequence comprised in a polypeptide, said polypeptide  
20 being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, and/or *Borrelia afzelii* ACAI but being substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, or *Borrelia hispanica*. It is preferred that said polypeptide is a protein having an apparent molecular weight of 13 kDa, and it is  
25 still more preferred that the encoded polypeptide fragment comprises at least one epitope (such as at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or at least 25 epitopes) being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI but being substantially absent from whole cell preparations of at least 95% of  
30 randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*. This at least one epitope is preferably one from a protein having an apparent molecular weight of 13 kDa.

By the terms "epitope" and "epitopic region" is meant the spatial part of an antigen  
35 responsible for the specific binding to the antigen-binding part of an antibody. It goes without saying that the identification of epitopes of the disclosed antigens will facilitate the production of polypeptides which exhibit marked antigenicity thus making them interesting with respect to diagnosis of Borreliosis and vaccination against infections with Bb; identification of epitopes has been discussed above.

Preferred nucleic acid fragments of the invention are DNA fragments, especially those which have nucleotide sequences with a sequence identity of at least 70% with SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 or with subsequences thereof of at least 12 nucleotides. However, the degree of sequence identity may be even higher such as at least 75%, 80%, 85%, 87%, and 89%. It is preferred that the degree of sequence identity is at least 90%, such as 92%, 94% or 95%, and especially preferred are DNA fragments with a sequence identity of at least 96% with SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22. Especially for high accuracy hybridization assays, a total sequence identity is necessary, and therefore preferred. Other preferred nucleotide acid fragments of the invention are those which encode a polypeptide of the invention (cf. the below discussions concerning these polypeptides and their degree of sequence identity with the amino acid sequences disclosed herein) which has an amino acid sequence exhibiting a sequence homology of at least 50% with SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23 or with subsequences thereof having a length of at least 10 amino acid residues. Also the sequence identity of the encoded polypeptide fragment is preferably higher, such as at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, and at least 96%.

The term "identity" is, with respect to nucleotide fragments such as DNA fragments, intended to indicate the identity between the nucleotides in question between which the identity is to be established, in the match with respect to nucleotide composition and position in the DNA fragments. With respect to polypeptides and fragments thereof described herein, the term means an identity between the amino acids in question between which the homology is to be established, in the match with respect to amino acid composition and their position in the polypeptides. The term "sequence identity" thus indicates a quantitative measure of the degree of homology between two amino acid sequences or between two nucleotide sequences of equal length: The

sequence identity can be calculated as 
$$\frac{(N_{ref} - N_{dif})}{N_{ref}} 100$$
 1, wherein  $N_{dif}$  is the total number of non-identical residues in the two sequences when aligned and wherein  $N_{ref}$  is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC will have a sequence identity of 75% with the sequence AATCAATC ( $N_{dif} = 2$  and  $N_{ref} = 8$ ).

Considerations similar to those given above for the immunological reactivity and cross-reactivity of antigens can be applied for the distinction between a nucleic acid fragment which "hybridizes readily" and a fragment which "exhibits substantially no hybridization" under high stringency conditions; *i.e.* a nucleic acid which hybridizes readily should exhibit at least 10% of a true positive signal.

As discussed in the examples, putative epitopes have been identified in the P13 protein sequences. Therefore, especially preferred nucleic acid fragments of the invention are those comprising a sequence encoding a polypeptide which comprises at least one amino acid sequence selected from the group consisting of amino acid residues 19-27, 33-36, 41-47, 95-104, 138-147 and 174-179 in SEQ ID NO: 19; amino acid residues 19-26, 32-35, 40-47, 94-101, 137-146, and 174-178 in SEQ ID NO: 21; and amino acid residues 18-26, 30-33, 39-46, 91-104, 137-145 and 173-177 in SEQ ID NO: 23, all of which have been identified as putative epitopic regions.

Highly preferred nucleic acid fragments are those which encode mature P13, *i.e.* nucleic acid fragments which encode a protein having an apparent molecular weight of 13 kDa which is present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI but which is substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*. Since this 13 kDa protein has been demonstrated in fraction B of Bb, it is preferred that this encoded protein is present in fraction B from *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI.

Analysis of the effects of exposure of whole Bb cells to proteinase K has now demonstrated that such Bb cells lose their reactivity with antibodies against the 13 kDa polypeptide and that fraction B of Bb cells are devoid of the 13 kDa protein. Hence, it must be concluded that P13 is a surface exposed polypeptide in Bb, and therefore preferred nucleic acid fragments are those which encode a surface exposed protein of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI.

Highly preferred embodiments of the nucleic acid fragments of the invention comprise a nucleotide sequence encoding a polypeptide fragment which includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 21, and 23, and of these, those which comprise a nucleotide sequence selected from the group consisting of SEQ ID NOs: 18, 20, and 22 are especially preferred. Most preferred nucleic acid fragments of the invention are those which consist of a nucleotide sequence

encoding a polypeptide fragment consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 21, and 23, and the three most preferred are those which consist of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 18, 20, and 22.

5

Analogues of the disclosed nucleic acid fragments which also form part of the invention are nucleic acid fragments which are fused to at least one other nucleic acid fragment which encodes a fusion partner. This fusion partner can be a protein enhancing the immunogenicity of the fused protein relative to a protein without the encoded fusion partner. Such encoded proteins may e.g. be lipoproteins, e.g. the outer membrane lipoprotein from *E. coli* and OspA from *Borrelia burgdorferi sensu lato*; viral proteins, e.g. from Hepatitis B surface antigen, Hepatitis B core antigen, and the influenza virus non-structural protein NS1 (cf. EP-A-O 366 238 and WO 88/01875); immunoglobulin binding proteins, e.g. protein A, protein G, and the synthetic ZZ-peptide (cf. EP-A-O 243 333 and US 5,411,732); T-cell epitopes; or B-cell epitopes.

Other nucleic acid fragments to form part of a nucleic acid fragment of the invention encoding a fusion polypeptide are those encoding polypeptides which facilitate expression and/or purification of the fused peptide. Such encoded polypeptides could, according to the invention, be bacterial fimbrial proteins, e.g. the pilus components pilin and papA; protein A; the ZZ-peptide; the maltose binding protein; glutathione S-transferase;  $\beta$ -galactosidase; calmodulin binding protein; or poly-histidine.

Other nucleic acid fragments to form part of a nucleic acid fragment of the invention encoding a fusion polypeptide are those encoding polypeptides which facilitate modulation in drug resistance of the host thereby facilitating selection of the host harbouring the plasmid. Such hosts could, according to the invention, be a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism selected from a fungus, an insect cell, a plant cell, and a mammalian cell.

Of course, also fusion partners derived from P13 are interesting and these could be those which have the same amino acid sequence as at least one amino acid sequence selected from the group consisting of amino acid residues 19-27, 33-36, 41-47, 95-104, 138-147 and 174-179 in SEQ ID NO: 19; amino acid residues 19-26, 32-35, 40-47, 94-101, 137-146, and 174-178 in SEQ ID NO: 21; and amino acid residues 18-26, 30-33, 39-46, 91-104, 137-145 and 173-177 in SEQ ID NO: 23

It will be understood from the above that various analogues and subsequences of the nucleic acids disclosed in the sequence listing herein are interesting aspects of the invention, as are nucleic acid fragments encoding fused polypeptides including polypeptides encoded by nucleic acid fragments of the invention.

5

The term "analogue" with regard to the nucleic acid fragments of the invention is intended to indicate a nucleotide sequence which encodes a polypeptide identical or substantially identical to a polypeptide encoded by a nucleic acid fragment of the invention (SEQ ID NOs: 18, 20, and 22).

10

It is well known that the same amino acid may be encoded by various codons, the codon usage being related, *inter alia*, to the preference of the organisms in question expressing the nucleotide sequence. Thus, one or more nucleotides or codons of a nucleic acid fragment of the invention may be exchanged by others which, when  
15 expressed, result in a polypeptide identical or substantially identical to the polypeptide encoded by the nucleic acid fragment in question.

Also, the term "analogue" is used in the present context to indicate a nucleic acid fragment or a nucleic acid sequence of a similar nucleotide composition or sequence  
20 as the nucleic acid sequence encoding the amino acid sequence having the immunological properties discussed above, allowing for minor variations which do not have an adverse effect on the biological function and/or immunogenicity as compared to the disclosed polypeptides, or which give interesting and useful novel binding properties or biological functions and immunogenicities etc. of the analogue. The analogous  
25 nucleic acid fragment or nucleic acid sequence may be derived from an animal or a human or may be partially or completely of synthetic origin as described herein. The analogue may also be derived through the use of recombinant nucleic acid techniques.

30 Furthermore, the terms "analogue" and "subsequence" are intended to allow for variations in the sequence such as substitution, insertion (including introns), addition, deletion and rearrangement of one or more nucleotides, which variations do not have any substantial effect on the polypeptide encoded by a nucleic acid fragment or a subsequence thereof. The term "substitution" is intended to mean the replacement of  
35 one or more nucleotides in the full nucleotide sequence with one or more different nucleotides, "addition" is understood to mean the addition of one or more nucleotides at either end of the full nucleotide sequence, "insertion" is intended to mean the introduction of one or more nucleotides within the full nucleotide sequence, "deletion" is intended to indicate that one or more nucleotides have been deleted from the



full nucleotide sequence whether at either end of the sequence or at any suitable point within it, and "rearrangement" is intended to mean that two or more nucleotide residues have been exchanged with each other.

#### 5 Polypeptide fragments of the invention

The present invention relates to the utility of Bb associated antigenic proteins as diagnostic or preventive tools in Lyme disease. Proteins have been identified as associated only (or predominantly) with virulent isolates of Bb, providing a basis for  
 10 several types of diagnostic tests for Lyme disease, including immunodiagnostic and nucleic acid identification, such as those based on amplification procedures. All these embodiments rely on the availability of the P13 proteins and their analogues.

Another part of the invention therefore pertains to a polypeptide fragment which  
 15 exhibits a substantial immunological reactivity with a polyclonal rabbit antibody raised against a polypeptide having an apparent molecular weight of 13 kDa as determined by SDS PAGE, followed by visualization, and being derived from *Borrelia burgdorferi* B313, said polypeptide comprising the amino acid sequence 1-167 of SEQ ID NO: 19, said polyclonal rabbit antibody exhibiting substantially no immunological reactivity  
 20 with whole cell preparations from at least 95% of randomly selected *B. hermsii*, *B. crocidurae*, *B. anserina*, or *B. hispanica*, with the proviso that said polypeptide is essentially free from other *Borrelia*-derived antigens when it is identical in amino acid sequence to a 13 kDa surface exposed polypeptide which can be extracted from *Borrelia burgdorferi sensu lato*.

25

As mentioned above, the 13 kDa polypeptide has previously been identified in SDS gels. However, the 13 kDa polypeptide has never been purified to homogeneity, let alone been cloned and sequenced. The present invention is therefore the first to provide the 13 kDa polypeptide in a form which is totally free from contaminating and  
 30 potentially harmful (for e.g. vaccine purposes) *Borrelia* antigens, *i.e.* the 13 kDa polypeptide in a substantially pure form. The present invention is also the first to provide useful variants of the 13 kDa polypeptide (such variants including subsequences of the polypeptide as well as analogues wherein changes have been made to the native amino acid sequence). It should be noted that it is highly problematic to purify  
 35 the native 13 kDa antigen to homogeneity since it is a membrane protein; it is well-known to the skilled person in protein purification that membrane proteins present special problems. However, upon the provision of recombinant or synthetic P13 as disclosed herein, it has become possible to readily prepare P13 in a form free of other *Borrelia* antigens and it has also become possible to prepare variants of P13 which

were not available without access to knowledge of the genetic material encoding the protein.

The polypeptide fragment of the invention is otherwise precisely as described above  
5 when discussing the nucleic acid fragments of the invention and all discussions  
pertaining to polypeptide fragments encoded by the nucleic acid fragments of the  
invention apply *mutatis mutandis* to the polypeptide fragments of the invention.  
Hence, all considerations regarding the presence or absence of the polypeptide frag-  
ments and their epitopes in various borrelial species as well as other considerations,  
10 apply to the polypeptide fragments of the invention.

Therefore, also analogues of the P13 polypeptides of the invention are embraced by  
the present invention. When using the terms "analogue" and "subsequence" in  
connection with polypeptides is meant any polypeptide having the same immuno-  
15 logical characteristics as the polypeptides of the invention described above with  
respect to the ability to confer an equivalent and increased resistance to infections  
with *Borrelia burgdorferi sensu lato* through immune responses against P13. Thus,  
included is also a polypeptide from different sources, such as other bacteria or even  
from eukaryotic cells.

20 The terms "analogue" and "subsequence" with regard to a polypeptide of the inven-  
tion are also used in the present context to indicate a protein or polypeptide of a  
similar amino acid composition or sequence as the characteristic amino acid sequen-  
ces shown in SEQ ID NOs: 19, 21 and 23, allowing for minor variations which do not  
25 have an adverse effect on the ligand binding properties and/or biological function  
and/or immunogenicity, or which may give interesting and useful novel binding pro-  
perties or biological functions and immunogenicities etc. The analogous polypeptide  
or protein may be derived from other microorganisms, cells, or animals and the  
analogue may also be derived through the use of recombinant DNA techniques as  
30 described herein.

The invention also comprises polypeptides which can be the product of post-trans-  
lational modifications of the polypeptides of the invention described above. By the  
term "post-translational modification" with regard to a polypeptide of the invention is  
35 meant any modification or processing of the full-length polypeptide that can occur  
during the production of the peptides in Bb, or in the case of recombinant polypep-  
tides in the production of the polypeptides in a host cell. These modifications include,  
but are not limited to, the processing by various peptidases, such as signal pepti-

dases, and modifications such as glycosylations, phosphorylations, acetylations, formylations, acylations, palmitylations, sulphations and lipidations.

Furthermore, in the present context the term “immunologically equivalent” means  
5 that the analogue or subsequence of the polypeptide is functionally equivalent to the  
polypeptide with respect to the ability of evoking a protective immune response  
against *Borrelia burgdorferi sensu lato* infections.

The term "protective immune response" has its usual meaning, i.e. that the immune response evoked by the polypeptide in question protects the person immunized from contracting Lyme disease, or that the immune response evoked by the polypeptide at least confers a substantially increased resistance to infections with *Borrelia burgdorferi sensu lato*.

15 Finally, also fusion polypeptides as described above are part of the invention and this is also true for all considerations relating to fusion partners etc. which are discussed above when dealing with the nucleic acid fragments of the invention.

### Vectors, host cells and cell lines of the invention

20 Having provided the genetic information relating to the P13 proteins, the invention also allows for the preparation of P13 and variants thereof by means of genetic engineering. Useful tools in this connection are cloning and expression vectors and therefore another important part of the invention is a non-borrelial vector carrying the

25 nucleic acid fragment according to the invention and described in detail above. Such a vector of the invention is preferably capable of autonomous replication. Preferred vectors are selected from the group consisting of a plasmid, a phage, a cosmid, a mini-chromosome, and a virus.

30 Even though plasmid vectors are often preferred because of their relative ease of use, vectors which, when introduced in a host cell, are integrated in the host cell genome are especially preferred due to the increased stability of the obtained transformed cells.

35 In view of the discussion below, a preferred vector of the invention comprises, in the 5'→3' direction and in operable linkage, a promoter for driving expression of the nucleic acid fragment of the invention, a nucleic acid sequence encoding a leader peptide enabling secretion of or integration into the membrane of the polypeptide, the nucleic acid fragment according to the invention, and a nucleic acid sequence

encoding a terminator. It is preferred that the promoter drives expression in a eukaryotic cell and also that the leader peptide enables secretion from or integration into the membrane of a mammalian cell.

- 5 The invention also relates to a transformed cell carrying the vector of the invention and capable of replicating the nucleic acid fragment according to the invention. Such a transformed cell is preferably a microorganism selected from a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism selected from a fungus, an insect cell, a plant cell, and a mammalian cell. Especially preferred host cells are
- 10 bacteria of the genera *Escherichia*, *Bacillus* or *Salmonella*. *E. coli* is preferred. Host cells which are capable of mediating a post-translational modification important for the biological function of the polypeptide of the invention are also a part of the invention.
- 15 For the purposes of production of recombinant P13 and variants thereof, a stable cell line is preferred and therefore the invention also relates to a stable cell line producing the polypeptide of the invention, which carries a vector of the invention, and which expresses the nucleic acid fragment of the invention.
- 20 In general, of course, prokaryotes are preferred for the initial cloning of DNA sequences and constructing the vectors useful in the invention. For example, in addition to the particular strains mentioned in the specific disclosure below, one may, by way of example, mention strains such as *E. coli* K12 strain 294 (ATCC No. 31446), *E. coli* B, and *E. coli* X 1776 (ATCC No. 31537). These examples are, of course, intended to
- 25 be illustrative rather than limiting.

Prokaryotes are preferred for expression. The aforementioned strains, as well as *E. coli* W3110 (F-, lambda-, prototrophic, ATCC No. 273325), bacilli such as *Bacillus subtilis*, or other enterobacteriaceae such as *Salmonella typhimurium* or *Serratia mar-*

30 *censcens*, and various *Pseudomonas* species may be used.

In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences

35 which are capable of providing phenotypic selection in transformed cells. For example, *E. coli* is typically transformed using pBR322, a plasmid derived from an *E. coli* species (see, e.g., Bolivar et al., 1977). The pBR322 plasmid contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR plasmid or another microbial plasmid or phage must also

contain, or be modified to contain, promoters which can be used by the micro-organism for expression.

The promoters most commonly used in recombinant DNA construction include the  $\beta$ -lactamase (penicillinase) and lactose promoter systems (Chang et al., 1978; Itakura et al., 1977; Goeddel et al., 1979) and a tryptophan (trp) promoter system (EP-B-0 036 776). While these are the most commonly used, other microbial promoters have been discovered and utilised, and details concerning their nucleotide sequences have been published, enabling a skilled worker to ligate them functionally with plasmid vectors (Siebenlist et al., 1980). Certain genes from prokaryotes may be expressed efficiently in *E. coli* from their own promoter sequences, thus avoiding the need for addition of another promoter by artificial means.

In addition to prokaryotes, eukaryotic microbes, such as yeast cultures may also be used. *Saccharomyces cerevisiae*, or common baker's yeast is the most commonly used among eukaryotic microorganisms, although a number of other strains are commonly available. For expression in *Saccharomyces*, the plasmid YRp7, for example, is commonly used (Stinchcomb et al., 1979; Kingsman et al., 1979; Tschumper et al., 1980). This plasmid already contains the trp1 gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC No. 44076 or PEP4-1 (Jones, 1977). The use of the trp1 lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.

Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase (Hitzeman et al., 1980) or other glycolytic enzymes (Hess et al., 1968; Holland et al., 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. In constructing suitable expression plasmids, the termination sequences associated with these genes are also ligated into the expression vector 3' of the sequence desired to be expressed to provide polyadenylation of the mRNA and termination.

Other promoters, which have the additional advantage of transcription controlled by growth conditions, are the promoter region for alcohol dehydrogenase 2, isocytocrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and the aforementioned glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilisation. Any plasmid vector

containing a yeast-compatible promoter, origin of replication and termination sequences is suitable.

In addition to microorganisms, cultures of cells derived from multicellular organisms may also be used as hosts. In principle, any such cell culture is workable, whether from vertebrate or invertebrate culture. However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years. Examples of such useful host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and W138, BHK, COS-7, 293 and MDCK cell lines.

Expression vectors for such cells ordinarily include (if necessary) an origin of replication, a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences.

For use in mammalian cells, the control functions on the expression vectors are often provided by viral material. For example, commonly used promoters are derived from polyoma, Adenovirus 2, and most frequently Simian Virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication (Fiers et al., 1978). Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the HindIII site toward the BglII site located in the viral origin of replication. Further, it is also possible, and often desirable, to utilise promoter or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell systems.

An origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viruses (e.g., Polyoma, Adeno, VSV, BPV) or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

Methods of producing the polypeptides of the invention which are themselves part of the invention thus comprise the following steps:

- culturing a transformed cell or a stable cell line according to the invention under conditions facilitating the expression of the polypeptide by the cell or cell line, and
  - 5 - harvesting the polypeptide, and optionally subjecting the polypeptide to post-translational modification(s);
- or, alternatively,
- 10 - synthesising the polypeptide by solid-phase peptide synthesis or by liquid-phase peptide synthesis.

The latter approach is preferred with the present technology when the polypeptide fragment is relatively short, but of course it cannot be excluded that these techniques  
15 will ultimately be refined so as to allow feasible production of longer fragments.

The need for post-translational modifications exists because certain polypeptides are prepared in the above-described manner lacking for instance a fatty-acylation of an amino acid residue, or the polypeptide has for some reason been prepared in an  
20 elongated version which should be cleaved before the polypeptide will prove functional. The optional post-translational modifications thus preferably involve lipidation or glycosylation when these modifications have not been accomplished by means of the preparative procedure itself. Applicable methods for accomplishing lipidation and/or glycosylation are well-known to the skilled person. Other post-translational  
25 modifications include cleavage or elongation of the obtained product. In some instances, the host cell or cell line also processes the translation product so as to obtain a processed polypeptide.

#### Preparation of useful variants of P13

30

The present invention has addressed the cloning of nucleic acids encoding certain antigenic polypeptides related to the P13 proteins.

A method of preparing variants of the P13 antigens is site-directed mutagenesis. This  
35 technique is useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, derived from the P13 antigen sequences, through specific mutagenesis of the underlying DNA. The technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence

changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to  
5 form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.

In general, the technique of site-specific mutagenesis is well known in the art as  
10 exemplified by publications (Adelman et al., 1983). As will be appreciated, the technique typically employs a phage vector which exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage (Messing et al., 1981). These phages are readily commercially available and their use is generally well known to those skilled in the  
15 art.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector which includes within its sequence a DNA sequence which encodes the P13 antigens. An oligonucleotide primer bearing the  
20 desired mutated sequence is prepared, generally synthetically, for example by the method of Crea et al. (1978). This primer is then annealed with the single stranded vector, and subjected to DNA polymerising enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated  
25 sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

30 The preparation of sequence variants of the selected P13 genes using site-directed mutagenesis is provided as a means of producing potentially useful species of the P13 genes and is not meant to be limiting as there are other ways in which sequence variants of the P13 genes may be obtained. For example, recombinant vectors comprising the desired P13 genes may be treated with mutagenic agents to obtain se-  
35 quence variants (see, e.g., a method described by Eichenlaub, 1979) for the mutagenesis of plasmid DNA using hydroxylamine.

Further, another embodiment of the invention is a nucleic acid fragment substantially identical to a nucleic acid fragment of the invention which can be provided e.g. by



dual hybridisation. This method employs a nucleic acid fragment which specifically hybridizes under stringency hybridization conditions to a complementary nucleic acid fragment which in turn specifically hybridizes under stringency hybridization conditions to a third nucleic acid fragment encoding a polypeptide comprising the amino acid sequences of the invention. This third nucleic acid fragment will thus be substantially identical to initial nucleic acid fragment.

#### Vaccine Preparation and Use

10 Part of the present invention contemplates vaccine preparation and use. General concepts related to methods of preparation and use are discussed as applicable to preparations and formulations with the disclosed P13 antigens, its epitopes and subfragments thereof. In general, a vaccine of the invention comprises an amount of a polypeptide of the invention or produced according to the invention, said amount  
15 being effective to confer substantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in an animal, including a human being, the polypeptide being formulated in combination with a pharmaceutically acceptable carrier, diluent or vehicle and the vaccine optionally further comprising an adjuvant. Further, the vaccine is generally used in a method of immunizing an animal, including a human being,  
20 against infections with *Borrelia burgdorferi sensu lato*, the method comprising administering an immunogenically effective amount of the vaccine to the animal.

Preparation of vaccines which contain peptide sequences as active ingredients is generally well understood in the art, as exemplified by U.S. Patents 4,608,251;  
25 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all incorporated herein by reference. In general terms, the preparation of the vaccines of the invention is accomplished by admixing

- a polypeptide of the invention or prepared by the method thereof, and  
30
- a pharmaceutically acceptable carrier, vehicle, or diluent, and optionally
- an adjuvant.

35 Typically, such vaccines are prepared as injectables either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for

example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the vaccines.

5

Suitable carriers are selected from the group consisting of a polymer to which the polypeptide(s) is/are bound by hydrophobic non-covalent interaction, such as a plastic, e.g. polystyrene, or a polymer to which the polypeptide(s) is/are covalently bound, such as a polysaccharide, or a polypeptide, e.g. bovine serum albumin, ovalbumin or keyhole limpet haemocyanin. Suitable vehicles are selected from the group consisting of a diluent and a suspending agent.

The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10-95% of active ingredient, preferably 25-70%.

The proteins may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the peptide) which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

The vaccines are administered in a manner compatible with the dosage formulation, and in such an amount as will be therapeutically effective and immunogenic. The quantity to be administered depends on the subject to be treated, including, e.g., the capacity of the individual's immune system to synthesise antibodies, and the degree of protection desired. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner. However, suitable dosage ranges

are of the order of several hundred micrograms of active ingredient per vaccination. For example, suitable dosages can be in the range of 1-1000  $\mu\text{g}$ , such as between 2 and 750  $\mu\text{g}$ , between 5 and 500  $\mu\text{g}$ , between 7.5 and 250  $\mu\text{g}$ , between 10 and 150  $\mu\text{g}$ , between 10 and 100  $\mu\text{g}$ , between 10 and 75  $\mu\text{g}$ , and between 10 and 50  $\mu\text{g}$ .

- 5 Suitable regimes for initial administration and booster shots are also variable but are typified by an initial administration followed by subsequent inoculations or other administrations.

The manner of application may be varied widely. Any of the conventional methods  
10 for administration of a vaccine are applicable. These are believed to include oral application on a solid physiologically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection or the like. The dosage of the vaccine will depend on the route of administration and will vary according to the size of the host.

- 15 Various methods of achieving adjuvant effect for the vaccine include use of agents such as aluminium hydroxide or phosphate (alum), commonly used as 0.05 to 0.1 percent solution in phosphate buffered saline, admixture with synthetic polymers of sugars (Carbopol) used as 0.25 percent solution, aggregation of the protein in the vaccine by heat treatment with temperatures ranging between 70°C and 101°C for  
20 30 second to 2 minute periods, respectively. Aggregation by reactivating with pepsin treated (Fab) antibodies to albumin, mixture with bacterial cells such as *C. parvum* or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block  
25 substitute may also be employed. The adjuvant is preferably selected from the group consisting of dimethyldioctadecylammonium bromide (DDA), Quil A, poly I:C, Freund's incomplete adjuvant, IFN- $\gamma$ , IL-2, IL-12, monophosphoryl lipid A (MPL), and muramyl dipeptide (MDP).

- 30 In many instances, it will be desirable to have multiple administrations of the vaccine, usually not exceeding six vaccinations, more usually not exceeding four vaccinations and preferably one or more, usually at least about three vaccinations. The vaccinations will normally be at from two to twelve week intervals, more usually from three to five week intervals. Periodic boosters at intervals of 1-5 years, usually three years,  
35 will be desirable to maintain levels of the antibodies. The course of the immunisation may be followed by assays for antibodies for the supernatant antigens. The assays may be performed by labelling with conventional labels, such as radionuclides, enzymes, fluorescers, and the like. These techniques are well known and may be

found in a wide variety of patents, such as U.S. Patent Nos. 3,791,932; 4,174,384 and 3,949,064, which are illustrative of these types of assays.

The polypeptide of the invention can also be part of a multi-component or combination vaccine, which is also an important part of the invention. Such a vaccine contains

an amount of the polypeptide fragment of the invention or of a polypeptide fragment prepared according to the invention, the amount of the polypeptide fragment being effective to confer substantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in an animal, including a human being; and

at least one further *Borrelia* antigen,

the polypeptide fragment and the antigen being formulated in combination with a pharmaceutically acceptable carrier, vehicle, or diluent and the vaccine optionally further comprising an adjuvant. All components of such a vaccine apart from the at least one further *Borrelia* antigen are as described in detail herein. With respect to the at least one further *Borrelia* antigen, it is preferred that it is selected from the group consisting of OspA, OspB, OspC, OspD, OspE, OspF, OspG, PC, Oms28, Oms45, Oms 66, decorin binding protein (dbp), LpLA7, EppA, T5, S1, 26 kDa, 39 kDa, 66 kDa, 79 kDa, 85 kDa, and 110 kDa antigen.

Another variant of a combination vaccine of the invention comprises at least two non-identical polypeptide fragments of the present invention or at least two non-identical polypeptide fragments prepared by the method of the invention, the vaccine comprising an amount of the polypeptides effective to confer substantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in an animal, including a human being, in combination with a pharmaceutically acceptable carrier, vehicle, or diluent, the vaccine optionally further comprising an adjuvant. Also in this case, all components of the vaccine have been described elsewhere herein.

Another known way of achieving a suitable immune response in a vaccinated animal is by employing a so-called live vaccine which *i.a.* triggers both a B- and a T-cell mediated immune response, and therefore the invention also pertains to such a vaccine comprising a non-pathogenic microorganism carrying and being capable of expressing the nucleic acid fragment of the invention so as to produce the polypeptide of the invention, the live vaccine being effective in conferring increased resistance to

—

•

•

[illegible]

—

Thus, a DNA vaccine or immunological composition, expressing a *P13* antigen, from *Borrelia burgdorferi*, *Borrelia afzelii* or *Borrelia garinii* or any combination thereof, can protect mice against infection by a *Borrelia* genospecies, the etiologic agent of Lyme disease. The composition is thus useful for eliciting a protective response in a host susceptible to Lyme Disease, as well as for eliciting antigens and antibodies, which are also useful in and of themselves.

Therefore, as discussed above, the invention in a general sense preferably provides methods for immunising, or vaccinating, or eliciting an immunological response in a host, such as a host susceptible to Lyme disease, e.g., a mammalian host, against *Borrelia* and accordingly Lyme Disease, by administering DNA encoding a P13 antigen, for instance DNA encoding P13 from *Borrelia burgdorferi*, *Borrelia afzelii*, *Borrelia garinii* antigen or combinations thereof, in a suitable carrier or diluent, such as saline; and the invention provides plasmids and compositions for performing the method, as well as methods for making the plasmids, and uses of the expression products of the plasmids, as well as antibodies elicited thereby.

From present dog and human trials based on efficiency studies with mice (Erdile et al., 1993; USSN 08/373,455), it is clear that mice are now a suitable animal model with respect to *Borrelia* and Lyme disease for extrapolation to domestic animals, humans, and other animals susceptible to Lyme disease or *Borrelia* infection (e.g., wild animals such as deer).

—

As broadly discussed above, the invention also pertains to plasmids comprising DNA including P13 encoding DNA for expression by eukaryotic cells. The DNA, from upstream to downstream (5' to 3'), can comprise: DNA encoding a promoter for

driving expression in eukaryotic cells, DNA encoding a leader peptide which enables secretion of a prokaryotic protein sequence from a mammalian cell, DNA encoding a P13 antigen (or antigens) or an immunologically active fragment thereof, DNA encoding other Bb antigens such as OspA, OspB, OspC or OspD or an immunologically active fragment thereof, and DNA encoding a terminator.

For instance, the promoter can be a eukaryotic viral promoter such as a herpes virus promoter, e.g., human cytomegalovirus promoter DNA.

- 10 The DNA encoding a leader peptide which enables secretion of a prokaryotic protein sequence from a mammalian cell is any DNA encoding any suitable leader for this purpose such as DNA encoding a eukaryotic, preferably mammalian, leader sequence; for instance, DNA encoding a leader peptide of a peptide hormone, or, for example, of insulin, renin, Factor VIII, TPA, and the like, with DNA encoding human tissue plasminogen activator (TPA) leader peptide being presently preferred.

The human cytomegalovirus promoter can be an immediate early human cytomegalovirus promoter such as HCMV-IE. As to HCMV promoters, reference is made to U.S. Patents Nos. 5,168,062 and 5,385,839. The plasmid of the invention can contain the HCMV-IE gene 5' untranslated region (UTR) which includes Intron A. This sequence can be 3' to the HCMV-IE promoter and 5' to the activator portion of the 5' UTR sequence and leader peptide. The TPA sequence can be derived from the TPA gene and can encode a portion of the 5' UTR and leader peptide from that gene. The 5' UTR of TPA may increase eukaryotic cell expression.

25

The transcriptional terminator sequence can be any suitable terminator, such as a eukaryotic terminator, for instance, DNA encoding a terminator for a mammalian peptide, with the BGH terminator being presently preferred.

- 30 The plasmid can be in admixture with any suitable carrier, diluent or excipient such as sterile water, physiological saline, and the like. Of course, the carrier, diluent or excipient should not disrupt or damage the plasmid DNA.

The plasmid can be administered in any suitable manner. The plasmid can be in a composition suitable for the manner of administration. The compositions can include: liquid preparations for orifice, e.g., oral, nasal, anal, vaginal, peroral, intragastric administration and the like, such as solutions, suspensions, syrups, elixirs; and liquid preparations for parenteral, subcutaneous, intradermal, intramuscular, intravenous administration, and the like, such as sterile solutions, suspensions or emulsions, e.g.,

for administration by injection. Intramuscular administration and compositions therefor are presently preferred.

The plasmids of the invention can be used for *in vitro* expression of antigens by eukaryotic cells. Recovery of such antigens can be by any suitable techniques; for instance, techniques analogous to the recovery techniques employed in the documents cited herein (such as the applications cited under Related Applications and the documents cited therein).

- 10 The thus expressed antigens can be used in immunological, antigenic or vaccine compositions, with or without an immunogenicity-enhancing adjuvant ("expressed antigen compositions"). Such compositions can be administered in dosages and by techniques well known to those skilled in the medical or veterinary arts taking into consideration such factors as age, sex, weight, species, condition of the particular
- 15 patient, and the route of administration. These compositions can be administered alone or with other compositions, and can be sequentially administered, e.g., each spring as the "Lyme Disease season" is about to begin.

- The route of administration for the expressed antigen compositions can be oral,
- 20 nasal, anal, vaginal, peroral, intragastric, parenteral, subcutaneous, intradermal, intramuscular, intravenous, and the like.

- The expressed antigen compositions can be solutions, suspensions, emulsions, syrups, elixirs, capsules (including "gelcaps" – a gelatin capsule containing a liquid
- 25 antigen or fragment thereof - preparations), tablets, hard-candy-like preparations, and the like. The expressed antigen compositions may contain a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose or the like. The compositions can also be lyophilised. The compositions can contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, adjuvants, gelling or
- 30 viscosity enhancing additives, preservatives, flavouring agents, colours, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as Remington: The Science and Practice of Pharmacy, 19<sup>th</sup> ed., Gennaro, AR, 1995, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.

35

Suitable dosages for plasmid compositions and for expressed antigen compositions can also be based upon the examples below, and upon the documents cited herein. For example, suitable dosages can be in the range of 1-1000 µg, such as between 2 and 750 µg, between 5 and 500 µg, between 7.5 and 250 µg, between 10 and 150



µg, between 10 and 100 µg, between 10 and 75 µg, and between 10 and 50 µg, in expressed antigen compositions. In plasmid compositions, the dosage should be a sufficient amount of plasmid to elicit a response analogous to the expressed antigen compositions; or expression analogous to dosages in expressed antigen compositions.

- 5 For instance, suitable quantities of plasmid DNA in plasmid compositions can be 0.1 to 2 mg, preferably 1-10 µg.

Thus, in a broad sense, the invention further provides a method comprising administering a composition containing plasmid DNA including DNA encoding a P13 antigen  
10 or antigens, for expression of the antigen or antigens *in vivo* for eliciting an immunological, antigenic or vaccine (protective) response by a eukaryotic cell; or for *ex vivo* or *in vitro* expression (that is, the cell can be a cell of a host susceptible to Lyme Disease, i.e., the administration can be to a host susceptible to Lyme Disease such as a mammal, e.g., a human; or the cell can be an *ex vivo* or *in vitro* cell). The invention  
15 further provides a composition containing a P13 antigen or antigens from expression of the plasmid DNA by a eukaryotic cell, *in vitro* or *ex vivo*, and methods for administering such compositions to a host mammal susceptible to Lyme disease to elicit a response.

- 20 Since the methods can stimulate an immune or immunological response, the inventive methods can be used for merely stimulating an immune response (as opposed to also being a protective response) because the resulting antibodies (without protection) are nonetheless useful. From eliciting antibodies, by techniques well-known in the art, monoclonal antibodies can be prepared and the monoclonal antibodies can be em-  
25 ployed in well known antibody binding assays, diagnostic kits or tests to determine the presence or absence of a P13 antigen or to determine whether an immune response to the bacteria has simply been stimulated. The monoclonal antibodies can also be employed in recovery or testing procedures, for instance, in immunoadsorption chromatography to recover or isolate a P13 antigen.

30

- To prepare the inventive plasmids, the DNA therein is preferably ligated together to form a plasmid. For instance, the promoter, leader sequence, antigen and terminator DNA is preferably isolated, purified and ligated together in a 5' to 3' upstream to downstream orientation. A three-way ligation, as exemplified below, is presently  
35 preferred.

### Nucleic Acid Hybridisation Embodiments

Also contemplated within the scope of the present invention is the use of the disclosed DNA as a hybridization probe. While particular examples are provided to  
5 illustrate such use, the following provides a general background for hybridization applications taking advantage of the disclosed nucleic acid sequences of the invention.

As mentioned, in certain aspects, the DNA sequence information provided by the  
10 invention allows for the preparation of relatively short DNA (or RNA) sequences having the ability to specifically hybridise to Bb gene sequences. In these aspects, nucleic acid probes of an appropriate length are prepared based on a consideration of the sequence, e.g., SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22 or derived from flanking regions of these genes. The ability of such nucleic acid probes to speci-  
15 fically hybridise to the Bb gene sequences lend them particular utility in a variety of embodiments. Most importantly, the probes can be used in a variety of diagnostic assays for detecting the presence of pathogenic organisms in a given sample. However, other uses are envisioned, including the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic  
20 constructs.

To provide certain of the advantages in accordance with the invention, the preferred nucleic acid sequence employed for hybridization studies or assays includes sequences that are complementary to at least a 10 to 40, or so, nucleotide stretch of the  
25 selected sequence, such as that shown in SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22. A size of at least 10 nucleotides in length helps to ensure that the fragment will be of sufficient length to form a duplex molecule that is both stable and selective. Molecules having complementary sequences over stretches more than 10 bases in length are generally preferred, though, in order to increase stability and  
30 selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. Thus, one will generally prefer to design nucleic acid molecules having gene-complementary stretches of 15 to 20 nucleotides, or even longer where desired. Such fragments may be readily prepared by, for example, directly synthesising the fragment by chemical means, by application of nucleic acid  
35 reproduction technology, such as the PCR technology of U.S. Patent 4,603,102, or by introducing selected sequences into recombinant vectors for recombinant production.

The present invention will find particular utility as the basis for diagnostic hybridization assays for detecting Bb-specific RNA or DNA in clinical samples. Exemplary clinical samples that can be used in the diagnosis of infections are thus any samples which could possibly include nucleic acid, including samples from tissue, blood, serum, urine or the like. A variety of tissue hybridization techniques and systems are known which can be used in connection with the hybridization aspects of the invention, including diagnostic assays such as those described in Falkow et al., U.S. Patent 4,358,535.

Accordingly, the nucleotide sequences of the invention are important for their ability to selectively form duplex molecules with complementary stretches of Bb gene segments. Depending on the application envisioned, one will desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of the probe toward the target sequence. For applications requiring a high degree of selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, for example, one will select relatively low salt and/or high temperature conditions, such as provided by 0.02M-0.15M NaCl at temperatures of 50°C to 70°C. These conditions are particularly selective and tolerate little, if any, mismatch between the probe and the template or target strand.

Of course, for some applications, for example where one desires to prepare mutants employing a mutant primer strand hybridised to an underlying template, less stringent hybridization conditions are called for in order to allow formation of the heteroduplex. In these circumstances, one would desire to employ conditions such as 0.15M-0.9M salt, at temperatures ranging from 20°C to 55°C. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide which serves to destabilise the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily manipulated, and will thus generally be a method of choice depending on the desired results.

In clinical diagnostic embodiments, nucleic acid sequences of the present invention are used in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of giving a detectable signal. In preferred diagnostic embodiments, one will likely desire to employ an enzyme tag such as alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents. In the case of enzyme tags, colorimetric indicator substrates are known which are employed to

provide a means visible to the human eye or spectrophotometrically to identify specific hybridization with pathogenic nucleic acid-containing samples. Luminescent substrates, which give off light upon enzymatic degradation, could also be employed and may provide increased sensitivity.

5

In general, it is envisioned that the hybridization probes described herein will be useful both as reagents in solution hybridization as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the test DNA (or RNA) from suspected clinical samples, such as exudates, body fluids (e.g., amniotic fluid, cerebrospinal fluid) or even tissues, is adsorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required (depending, for example, on the G + C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.). Following washing of the hybridised surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label.

Furthermore, it is envisioned that synthetic single stranded nucleotides can be produced (by a series of photolithographic and chemical steps) on a solid phase based on nucleic acid sequences or the complementary sequence of the invention and sequences comprised thereof. Single-stranded nucleic acid fragments from suspected clinical samples, such as exudates, body fluids (e.g., amniotic fluid, cerebrospinal fluid) or even tissues are then subjected to specific hybridisation under desired conditions.

These single-stranded nucleic acid fragments are labeled for detection prior to hybridisation. The selected conditions for hybridisation will depend on the particular circumstances based on the particular criteria required (depending, for example, on the G + C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.). Following washing of the hybridised surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label.

The invention discloses a DNA segment encoding an antigenic Bb protein. Detection of that DNA or various parts thereof is expected to provide the basis for a useful amplification assay. One method of detecting the P13 antigen genes is based on selective amplification of known portions of the gene. A particular method utilises PCR amplification, using any one of a number of primers that could be prepared from knowledge of the nucleic acid sequence of SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22. Generally, such primers are relatively short, e.g., 7-28 base pairs in

length, and may be derived from the respective sense or anti-sense strands of the disclosed DNA segment. Synthesis of these primers may utilise standard phosphoramidite chemistry (Beaucage et al., 1981).

- 5 In summary, this part of the invention relates to a diagnostic composition adapted for the determination of *Borrelia burgdorferi sensu lato* in a sample, the composition comprising an amount of the nucleic acid fragment of the invention which is effective to detectably bind to a nucleic acid fragment from *Borrelia burgdorferi sensu lato* present in the sample, the composition optionally comprising a detectable label.

10

Further, another embodiment of the invention is a method of determining the presence of *Borrelia burgdorferi sensu lato* nucleic acids in a sample, comprising incubating the sample with the nucleic acid fragment of the invention, and detecting the presence of hybridized nucleic acids resulting from the incubation. Alternatively, such

- 15 a method comprises subjecting the nucleic acid fragment of the invention to a molecular amplification reaction, such as PCR, and detecting the presence of amplified nucleic acid which is specific for *Borrelia burgdorferi sensu lato*.

Finally, the invention also provides a diagnostic kit comprising

20

- a nucleic acid fragment of the invention and a means for detecting the binding between the nucleic acid fragment and nucleic acid bound thereto, or
  - a set of nucleic acid primers which, when used in a molecular amplification
- 25 procedure together with the nucleic acid fragment of the invention, will result in specific amplification of said nucleic acid fragment, and a means for detecting the amplified nucleic acid fragment.

#### Diagnostic immunological embodiments

30

Antibodies could be produced and used for screening strains for protein expression, for determining structural location and for examining bactericidal activity of antibodies against these proteins. Means and measures for producing both monoclonal and polyclonal antibodies against P13 are easily applied by the skilled person on the

35 basis of the teachings herein.

It is contemplated that several assays for Lyme disease may be developed using any of the P13 proteins or its epitopes, the corresponding DNA encoding the protein, functionally similar proteins and their epitopes, or by detection of the appropriate

mRNA. An indirect ELISA assay could be used with the P13 protein or other antigenic proteins. These methods are similar in principle to those previously described (Magne-  
narelli et al., 1989; Craft et al., 1984; Bergström et al., 1991). Reactive epitopes  
representing portions of the P13 protein sequences could be utilised in an analogous  
5 manner.

Another promising assay is the microcapsule agglutination technique (MCAT) (Arimitsu et al., 1991). In this procedure, microscopic polystyrene beads are coated with Bb antigen and incubated with dilutions of patient serum. After overnight incubation at  
10 4°C, the agglutination patterns are determined. Using whole Bb as antigen, the MCAT has been shown to be highly discriminatory between Lyme disease patients and healthy individuals, with little overlap in agglutination titre, although false positive reactions have been obtained with rheumatoid arthritis patients (Anderson et al., 1988) and leptospirosis samples (Barbour, 1988). An assay using P13 protein alone or  
15 in combination with other antigens such as the 94 kDa, 30 kDa and 21 kDa antigens should be feasible. Such a combination may increase sensitivity of the assay.

In summary, an embodiment of this part of the invention is a diagnostic composition adapted for the determination of *Borrelia burgdorferi sensu lato* in a sample, the com-  
20 position comprising the polypeptide of the invention or prepared thereby, the amount of the polypeptide being effective to detectably react with antibodies present in the sample, the antibodies being directed against *Borrelia burgdorferi sensu lato*, the composition optionally comprising a detectable label, e.g. as described above. Related to this is another embodiment of the invention, i.e. a method of determining the pre-  
25 sence of antibodies directed against *Borrelia burgdorferi sensu lato* in a sample, comprising incubating the sample with the polypeptide of the invention or prepared by the method of the invention, and detecting the presence of bound antibody resulting from the administration or incubation.

30 Finally, this part of the invention also pertains to a diagnostic kit comprising a polypeptide of the invention and a means for detecting the polypeptide with antibody bound thereto.

## 35 EXAMPLES

**Bacterial strains and culture conditions.** *Borrelia* strains used in this study were the following: strain B31 of *B. burgdorferi*, a tick isolate from North America (ATCC 35210); strain ACA1 of *B. afzelii*, a human skin isolate from Sweden (Åsbrink et al.,

1984); strain IP90 of *B. garinii*, a tick isolate from the Asian Russia (Kryuchevnikov et al., 1988); strain *B. burgdorferi* B313, a mutant of *B. burgdorferi* B31 lacking OspA, OspB, OspC and OspD (Sadziene et al., 1993).

- 5 Also used were three relapsing fever borreliae species, *B. hermsii*, *B. crocidurae*, and *B. hispanica*, as well as *B. anserina*, the causative agent of avian borreliosis.

Borreliae were grown in BSK II medium (Barbour, 1984) and the cells were harvested in late-log phase by centrifugation at 5,000 rpm for 20 min.

10

The *Escherichia coli* strains DH5 $\alpha$  and BL21 were used for transformation with the recombinant plasmids in DNA cloning and gene expression experiments, respectively. *E. coli* strains were grown in Luria broth medium (Gibco BRL, Gaithersburg, MD) supplemented, when required, with carbenicillin (Sigma, St. Louis, MO) at 50  $\mu$ g/ml.

15

Monoclonal antibodies 15G6 and 7D4 were obtained from Dr. Alan G. Barbour (Sadziene et al., 1994)

DNA fragments were sequenced by the dideoxy chain termination method, with ABI

- 20 PRISM™ Dye Terminator Cycle Sequencing Ready Reaction Kit, with AmpliTaq® DNA Polymerase, FS. The sequence fragments were assembled using the GCG software for UNIX computer.

#### EXAMPLE 1

25

*Preparation of Bb proteins, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and Western blot*

##### 1.1 Preparation of Bb proteins.

- 30 For the whole-cell protein preparations, bacteria harvested from 250 ml of BSK II medium were washed twice with phosphate-buffered saline-5mM MgCl<sub>2</sub> (PBS-Mg). The pellet was suspended in 2 ml of PBS, sonicated and the supernatant was collected after centrifugation at 10,000 rpm for 30 min.
- 35 The subcellular fraction of borreliae outer membrane components (designated Fraction B) was prepared as described elsewhere (WO 90/04411). Briefly, cells harvested from 1.5 l of the culture were washed three times with 10 mM Tris-HCl (pH 7.4), 150 mM NaCl and 5 mM MgCl<sub>2</sub> (TSM buffer). Octyl- $\beta$ -D-glucopyranoside (OGP) (Sigma St. Louis, MO) was added to a final concentration of 2% in 10 ml TSM buffer

and the suspension was incubated at 37°C for 60 min. The cell lysate was centrifuged and the supernatant was incubated at 56°C for 30 min. The precipitate was removed by centrifugation at 20,000 rpm for 30 min at 37°C, and the supernatant was dialysed against water at 4°C for 2 days. The precipitate (Fraction B) formed in the dialysis bag was recovered by centrifugation at 20,000 rpm for 30 min at 25°C.

### 1.2 Separation of proteins by SDS-PAGE.

Bacterial proteins were separated by 15% SDS-PAGE essentially according to Laemmli (1970). Subsequently, gels were either stained with Coomassie Blue R-250 (CB) (Sigma, St Louis, MO), silver-staining (BioRad Hercules, CA), or were subjected to Western blotting.

### 1.3 Western blotting.

The proteins were transferred to a PVDF-membrane (BioRad, Hercules, CA) by electroblotting at 0.8 mA/cm<sup>2</sup> for 1 h. The non-specific binding was blocked by immersing the filter for 2 h into 5% non-fat milk powder (Semper, Stockholm, Sweden) in PBS containing 0.05% Tween-20 (PBS-T). Primary or secondary antibodies were diluted with 2.5% milk-powder in PBS-T, and both incubations of the filter for 1 h were followed by washing in PBS-T. In a developing reaction the substrate for the alkaline phosphatase conjugate was 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Sigma, St. Louis, MO).

## EXAMPLE 2

### 25 Preparation of antiserum against the 13 kDa antigen

#### 2.1 Purification of the 13 kDa antigen.

A 13 kDa protein was purified by 15% SDS-PAGE of Fraction B obtained from the *B. burgdorferi* B313 spirochaetes. The appropriate band was visualised by staining the gel with 250 mM KCl in ice-cold water without fixation in MeOH and acetic acid. Elution of protein from the gel was performed in a Schleicher and Schuell Biotrap in 15 mM NH<sub>4</sub>HCO<sub>3</sub> (200V for 8 hr).

#### 2.2 Immunisation of rabbits.

A mixture of eluted protein and protein from a crushed SDS-PAGE gel of approximately 100 µg of the 13 kDa protein prepared as described above was homogenised and used in each of four immunisations of one rabbit performed at one and two (for the last immunisation) months intervals. Serum samples were obtained during a 5-month period, and serum was diluted 1:1,000 when used for Western blot analysis.



## EXAMPLE 3

*Cell surface proteolysis of Borrelia cells*

5

**3.1 Protease treatment of *Borrelia* cells.**

Cell surface proteolysis of Bb cells was conducted as previously described (Barbour et al., 1984). Briefly, washed spirochetes were resuspended in PBS-Mg at a concentration of  $2 \times 10^9$  cells/ml. To 950  $\mu$ l of the cell suspension was added 50  $\mu$ l of one of the following: distilled water, proteinase K (Sigma, St Louis, MO) (4 mg/ml in water) or trypsin (Gibco BRL, Gaithersburg, MD) (1 mg/ml in  $10^{-3}$  M HCl). After incubation for 40 min at 20°C, the proteolytic treatment was stopped by the addition of 10  $\mu$ l from a solution of the peptidase inhibitor phenylmethylsulfonyl fluoride (PMSF) (Sigma, St. Louis, MO) (50 mg of PMSF per 1 ml of isopropanol), and the cells were centrifuged and washed twice with PBS-Mg. The pellets were resuspended in TSM buffer. One-third of the cell suspension of each preparation was subjected to the whole cell protein extraction by boiling in SDS-PAGE sample buffer. The remaining part of the suspensions was used to prepare the subcellular fraction of the borrelial outer membrane components, Fraction B, as described above.

20

**3.2 Analysis of the protease treated *Borrelia* cells.**

The result of the protease treatment of Bb cells as analysed by SDS-PAGE is presented in Figure 1A, and followed by Western Blot, Figure 1B. As seen in the CB stained protein profiles of the whole-cell lysates (Figure 1A), proteinase K considerably affected the minor protein with an apparent molecular weight of 13 kDa. The protein composition of the subcellular fractions of outer membrane components (Fraction B) recovered from protease treated and untreated spirochaetes, was also investigated. The 13 kDa protein was shown to constitute a substantial part of the Fraction B obtained from the Bb cells. In the Fraction B derived from the proteinase K treated cells, the 13 kDa protein was entirely absent.

30

The finding that protease treatment eliminates the 13 kDa protein clearly shows that the 13 kDa protein is surface exposed, and most probably associated with the outer membrane of the Bb cells.

35

## EXAMPLE 4

*Immunogold labelling of Borrelia cells*

5 The monoclonal antibody 15G6 raised against the 13 kDa protein was used as the primary antibody for immunogold staining of intact *B. burgdorferi* B31 and *B. burgdorferi* B313. Cells from strain B31 (Figure 2A) were labelled to a minor extent than cells from the strain B313 (Figure 2B). This was probably due to the presence of outer surface proteins, i.e. OspA, OspB, OspC, OspD, on the surface of the B31  
10 cells. The labelling was confined to the outer surface membrane for both strains indicating that the 13 kDa protein is an outer surface protein.

## EXAMPLE 5

15 *Expression of the 13 kDa protein in different Borrelia species***5.1 SDS-PAGE analysis.**

The CB stained SDS-PAGE of the whole-cell protein preparations of Lyme disease borreliae is shown in Figure 1A. The 13 kDa protein was present in the whole-cell  
20 preparations (WC) and enriched in the membrane fraction (BF) of *B. burgdorferi* B31, *B. afzelii* ACAI, and *B. garinii* IP90. The PAGE revealed no major differences among the borrelial strains in respect of either apparent molecular weight or expression level of the 13 kDa protein. In the analogous preparations from *B. hermsii*, *B. crocidurae* and *B. anserina*, no visible band corresponding to the 13 kDa protein was detectable.  
25

**5.2 Western blotting.**

In Western blot analysis of Fraction B prepared from *B. burgdorferi* B31, *B. afzelii* ACAI and *B. garinii* IP90 (Figure 3A and 3B), the 13 kDa protein of *B. burgdorferi* B31 reacted with the monoclonal antibody 15G6. The monoclonal antibody failed to  
30 recognise the 13 kDa protein from *B. afzelii* ACAI, and *B. garinii* IP90 indicating that the antibody is directed against a variable epitope.

However, polyclonal rabbit antiserum (described in Example 2.2) was able to recognise the 13 kDa protein from all three Lyme Disease species, i.e. *B. burgdorferi*  
35 B31, *B. afzelii* ACAI and *B. garinii* IP90 (Figure 1B).

In another Western blot analysis the rabbit antiserum raised against the 13 kDa protein prepared from *B. burgdorferi* B313 did not recognise a 13 kDa protein or any

proteins of similar molecular weight from *B. hermsii* or *B. crocidurae* (Figure 1C), or *B. anserina* or *B. hispanica* (data not shown).

These data indicate that 13 kDa protein is unique for Lyme disease borreliae. Conversely, it was shown recently that the ospC gene homologues and OspC-related proteins are present in *Borrelia* species not associated with Lyme borreliosis (Marconi et al., 1993).

#### EXAMPLE 6

10

##### *Isolation and N-terminal amino acid sequencing of the 13 kDa protein*

###### **6.1 Amino acid sequencing.**

The 13 kDa protein band was isolated and cut from a SDS-PAGE gel and eluted in a Biotrap as described above, Example 2.1. N-terminal amino acid sequencing of the purified 13 kDa protein was attempted but no sequence was obtained. It was concluded that the N-terminus of the 13 kDa protein was blocked. Therefore, the purified protein was digested with *Staphylococcus aureus* V8 protease. The protein cleavage resulted in two fragments of about equal size. As one of the fragments is blocked, only one can be sequenced. After cleavage the fragments were transferred to a PVDF membrane (Biorad, Hercules, CA) by soaking the membrane in the protein solution over night. N-terminal amino acid sequence analysis was performed on a 477A sequenator (Applied Biosystems, Foster City, CA) at Umeå University.

N-terminal amino acid sequence of the peptide fragment obtained by protease cleavage of the 13 kDa protein, recovered from the Fraction B of *B. burgdorferi* B313, resulted in the following sequence

TSKQDPIVPFLLNLFLGFGIGSFAQ

(SEQ ID NO: 1)

30

###### **6.2 Design of oligonucleotide probe.**

The sequence of the 25 amino acid fragment was used to design two oligonucleotides, one designated Y5.2 (SEQ ID NO: 2), and one designated Y6.2 (SEQ ID NO: 3). Codons for the amino acid sequence obtained, SEQ ID NO: 1, were selected by reverse translation based on (1) conclusion that codons containing A or T were favoured and (2) knowledge of published DNA sequences for several Bb proteins. A choice favouring A or T containing codons was based on the observation that the G + C content of Bb is only 28-35% (Burman et al., 1990). These oligonucleotides were used in a PCR reaction with DNA prepared from *B. burgdorferi* B31 as template

and a 74 bp fragment was obtained. The PCR fragment was cloned into the T-vector (Novagen, Madison, WI) and sequenced, SEQ ID NO: 4. It was verified that the obtained PCR fragment coded for the N-terminal amino acid sequence of the peptide fragment obtained after protease cleavage of the 13 kDa protein, SEQ ID NO: 1.

- 5 Based on the sequence of the PCR fragment an oligonucleotide designated Y7 (SEQ ID NO: 5) was designed. This oligonucleotide was to be used as a probe.

#### EXAMPLE 7

##### 10 *Preparation of Bb DNA libraries*

###### **7.1 Extraction of DNA.**

- Spirochetes harvested from 400 ml of culture of *B. burgdorferi* B31, *B. burgdorferi* B313, *B. afzelii* ACAI, and *B. garinii* IP90 were washed twice with 50 mM Tris-HCl (pH = 7.4) and resuspended in 10 ml of buffer containing 50 mM Tris-HCl (pH = 7.4), 25% sucrose, and 50 mM EDTA. The cells were lysed by adding SDS to a final concentration of 2%, lysozyme (Sigma, St. Louis, MO) (1.5 mg/ml), proteinase K (Sigma, St. Louis, MO) (0.1 mg/ml), and RNAase A (Sigma, St Louis, MO) (10 µg/ml). The DNA was extracted with buffered phenol and ethanol precipitated.

20

###### **7.2 Construction of DNA libraries.**

- Restriction enzymes were obtained from Boehringer, Mannheim, Germany. 100 ng of borreliac DNA prepared as described above was completely or partially digested using *EcoRI* and *XbaI* restriction endonucleases separately. For the partial digestions, 1 U of restriction endonuclease was incubated with 100 ng of DNA for 10 min. at 37°C. Twenty nanograms of appropriately digested pUC19 (Pharmacia, Uppsala, Sweden) vector was used for ligations.

#### EXAMPLE 8

30

##### *Cloning and sequencing of the gene encoding the 13 kDa protein*

###### **8.1 Screening of a DNA library prepared from *B. burgdorferi*.**

The recombinant plasmids were transformed into competent *E. coli* DH5α cells.

- 35 Initially, a *B. burgdorferi* B31 and B313 *EcoRI* digested DNA library was screened with the DNA probe Y7 (SEQ ID NO: 5). This screening did not result in any positive clones.

An *RsaI* restriction site was identified in the sequence of the PCR fragment, SEQ ID NO: 4. This site was used in a further attempt to clone the gene encoding the 13 kDa protein as described below. DNA prepared from *B. burgdorferi* B31 was cut with *RsaI* and the fragment ligated into *HincII* digested pUC18 (Pharmacia, Uppsala, Sweden) plasmid. The oligonucleotide designated Y7 corresponding to the sequence downstream of the *RsaI* site, SEQ ID NO: 5, was used together with pUC primers forward and reversed (Pharmacia, Uppsala, Sweden) in a PCR reaction to obtain a DNA fragment corresponding to the downstream part of the gene coding for the 13 kDa protein. Another oligonucleotide designated Y7R corresponding to the sequence upstream of the *RsaI* site, SEQ ID NO: 6, was constructed and used together with the pUC primers forward and reversed in a PCR reaction with *EcoRI* digested DNA as template to obtain a DNA fragment corresponding to the upstream part of the gene coding for the 13 kDa protein. However, the obtained total sequence coded for a protein with a calculated molecular weight of 7 kDa. This did not correspond to the expected molecular weight of the full-length DNA fragment coding for the 13 kDa protein.

Therefore, a new oligonucleotide designated Y9, SEQ ID NO: 7, was designed and used together with the oligonucleotide Y7R, SEQ ID NO: 6, to generate a new PCR fragment. This PCR fragment was used as a probe to screen a library of *XbaI* digested DNA prepared from *B. burgdorferi* B31 in an attempt to isolate a full-length DNA fragment encoding the 13 kDa protein.

A recombinant plasmid designated pLY-100 recovered from one positive *E. coli* DH5 $\alpha$  clone was isolated. The DNA insert of this plasmid was sequenced and found to comprise a gene fragment containing 537 bp including an ATG start codon followed by an open reading frame (ORF), SEQ ID NO: 18.

## 8.2 Sequencing of a gene encoding the 13 kDa protein from *B. afzelii* ACAI and *B. garinii* IP90.

The full-length 13 kDa protein gene was retrieved by PCR amplification followed by ligation into a pT7Blue vector (Novagen, Madison, WI). Multiple amplifications were used to ensure that the DNA Taq polymerase did not introduce any errors in the sequence.

The following primer pairs and number of clones was used to obtain the full-length and double stranded sequence of the gene encoding the 13 kDa protein in *B. afzelii* ACAI and *B. garinii* IP90.

# of *B. afzelii* ACAIPrimer pairs<sup>b</sup>Primer pairs<sup>c</sup>

clones <sup>a</sup>		
1	Y9-Y18	SEQ ID NO:7 - SEQ ID NO: 13
1	Y9-CMV3	SEQ ID NO:7 - SEQ ID NO: 17
1	Y9-Y10	SEQ ID NO:7 - SEQ ID NO:8
3	Y12-Y10	SEQ ID NO: 10 - SEQ ID NO:8
2	Y13-CMV3	SEQ ID NO: 11 - SEQ ID NO: 17

# of <i>B. garinii</i> IP90 clones <sup>a</sup>	Primer pairs <sup>b</sup>	Primer pairs <sup>c</sup>
2	Y9-CMV2	SEQ ID NO:7 - SEQ ID NO: 16
1	Y12-Y10	SEQ ID NO: 10 - SEQ ID NO:8
1	Y11-Y10	SEQ ID NO:9 - SEQ ID NO:8
1	Y13-Y10	SEQ ID NO: 11 - SEQ ID NO:8
3	Y31-CMV2	SEQ ID NO: 14 - SEQ ID NO: 16

<sup>a</sup> Clones obtained by different PCR amplifications

<sup>b</sup> Primer pairs used in different PCR amplifications

<sup>c</sup> Primer pairs used identified by SEQ ID numbers

5

### 8.3 Sequence analysis.

Sequence analyses were performed using the University of Wisconsin GCG Sequence Analysis Software Version 7.2 for UNIX computer. Search in protein sequence data-  
10 bases was performed at the NCBI using the BLAST network service.

The nucleotide sequences of the gene encoding the 13 kDa protein of *B. burgdorferi* B31, *B. afzelii* ACAI, *B. garinii* IP90, are shown in SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, respectively. The ATG start codon was followed by an ORF of  
15 534 and 531 nucleotides for strains ACAI and IP90, respectively.

The nucleotide sequence of the gene encoding the 13 kDa protein of *B. burgdorferi* B313 was identical to the nucleotide sequence of the gene encoding the 13 kDa protein of *B. burgdorferi* B31.

20

The deduced amino acid sequences of the 13 kDa protein of *B. burgdorferi* B31, *B. afzelii* ACAI and *B. garinii* IP90 are presented in SEQ ID NO: 19, SEQ ID NO: 21 and SEQ ID NO: 23. The deduced amino acid sequences of the full-length protein consist of 179, 178 and 177 amino acids for the respective strain. The computer  
25 analysis predicted a potential leader peptidase II cleavage site between amino acid residues at position 12 and 13 (LXXF-C), and the N-terminal peak was found on the hydrophobicity plot (data not shown). Based on this and the fact that the protein was found to be N-terminally blocked, it could be concluded that the 13 kDa protein is a lipoprotein. However, no labelling of the 13 kDa protein with tritiated palmitate could

be detected in Bb. This might be explained by the relatively early location of the cysteine, i.e., position 13. Usually the lipoprotein acylation sites are located within the first 16-30 amino acids. Further computer analysis predicted a potential signal peptidase I cleavage site between amino acids 21 and 22 in both *B. burgdorferi* B31 and *B. afzelii* ACAI, while two potential cleavage sites, between amino acids 19 and 20, and between amino acids 21 and 22, were identified in *B. garinii* IP90. Surprisingly, the full-length P13 protein from the strains B31, ACAI and IP90 consisted of, respectively, 179, 178 and 177 amino acids with a calculated molecular weight of 19107 Da, 19197 Da and 19311 Da. The cleavage of the respective leader sequences recognized by signal peptidase I would yield a mature P13 protein composed of: 158 amino acids with a calculated molecular mass of 16,772 Da for *B. burgdorferi* B31; 157 amino acids with a molecular mass of 16,864 for *B. afzelii* ACAI; and 156 or 158 amino acids with molecular masses of 16,872 Da or 17,115 Da, respectively for *B. garinii* IP90, in contrast to the apparent molecular weight of 13 kDa observed on PAGE. It therefore seems likely that P13 is both post-translationally processed and modified. Further analysis, such as determination of C-terminal amino acid and total amino acid composition of the purified P13 protein, will be necessary to finally establish the nature of this modification and processing.

The amino acid sequence of the P13 protein from *B. burgdorferi* B31 was 87.9% and 87.5% identical to the sequences from *B. afzelii* ACAI and *B. garinii* IP90, respectively. When compared with each other, the two latter strains showed 90.5% identity.

The level of similarity and identity between the deduced amino acid sequence of the P13 protein from different *Borrelia* strains further shows that this protein can be useful as a vaccine against Lyme disease as well as a target for diagnostic use.

The P13 proteins were examined for the sequence similarity to other known proteins in database libraries. There were no other sequences related significantly to the P13 proteins. The best hit in an EMBL database search was a 95 residues long amino acid sequence encoded by the p11 gene on the Bb 49 kb linear plasmid. The encoded amino acid sequence was 41.5% identical in sequence in a 82 amino acid overlap (corresponding to amino acid residues -12 to 70 in SEQ ID NO: 19). For the purposes of reference, this best hits are included herein as SEQ ID NOs: 30 and 31. The P13 gene sequence was compared to the recently completed *B. burgdorferi* B31 genome (Fraser et al., 1997) and was found to be identical with an ORF called BB034. Four additional Bb proteins with a high degree of sequence identity to P13 were also found. Together with these putative peptides denoted BBA01, BBI31, BBH41 and

BBQ07, P13 belongs to a protein family designated paralogous family No. 5, formerly No. 48 (Fraser et al., 1997).

#### 8.4 Antigenicity plot.

- 5 Potential antigenic regions of the deduced amino acid sequences of the P13 proteins from *B. burgdorferi* B31, *B. afzelii* ACAI and *B. garinii* IP90 were identified by calculation of the antigenic index using the algorithm of Jameson and Wolf (1988). The results are shown in Figure 4. Proposed epitopic regions having a high antigenic index are e.g. the amino acid sequences corresponding to amino acid residues 19-27, 33-36, 41-47, 95-104, 138-147 and 174-179 in SEQ ID NO: 19; amino acid residues 19-26, 32-35, 40-47, 94-101, 137-146, and 174-178 in SEQ ID NO: 21; and amino acid residues 18-26, 30-33, 39-46, 91-104, 137-145 and 173-177 in SEQ ID NO: 23.

#### 15 EXAMPLE 9

##### *Localisation of the P13 protein gene*

#### 9.1 Separation of DNA by pulse-field agarose gel electrophoresis.

- 20 For the pulse-field AGE, the DNA prepared from *B. burgdorferi* B31, *B. burgdorferi* B313, *B. afzelii* ACAI and *B. garinii* IP90 was recovered in 1% agarose blocks as previously described (Ferdows and Barbour, 1989). One-dimensional AGE and pulse-field AGE were performed in 1% agarose in TBE buffer. For the pulse-field AGE pulse times were 0.5 s for 30 min, 8 s for 30 min, 1 s for 3 h, 2 s for 3 h, 4 s for 6 h, 8 s 25 for 8 h at a constant current of 200 V, see Figure 5A.

#### 9.2 Southern blotting.

- Following depurination, denaturation and neutralisation of the gels, the DNA was transferred to a Hybond-N membrane (Amersham, Buckinghamshire, UK) by the 30 method of Southern (Sambrook et al., 1989), and cross-linked with UV light. Filters were pre-hybridised and hybridised in 0.25 M Na<sub>2</sub>HPO<sub>4</sub> (pH=7.2), 1% BSA, 1mM EDTA, 7% SDS for 1 h and 4 h, respectively, and washed for 15 min in 5xSSC, 0.1% SDS; followed by 15 min in 2xSSC, 0.1% SDS; and 15 in 1xSSC, 0.1% SDS, at the hybridisation temperature. The temperature was 60°C for probing with a PCR 35 fragment obtained by amplification using the primers Y7R (SEQ ID NO: 6) and Y9 (SEQ ID NO: 7) (see above) [ $\alpha$ -<sup>32</sup>P]dATP (Amersham, Buckinghamshire, UK), radio-labeled by random primer technique.



The hybridising band corresponded to the position of the 1 Mbp linear chromosome of Lyme disease borreliae, see Figure 5B.

#### EXAMPLE 10

5

##### *Existence of a P13 homologue in related Borrelia species*

#### 10.1 DNA.

Total DNA from *B. burgdorferi*, *B. hermsii*, *B. crocidurae*, and *B. anserina* was  
10 digested with *EcoRI* and separated by AGE.

#### 10.2 Southern blotting.

Following depurination, denaturation and neutralisation of the gels, the DNA was transferred to a Hybond-N membrane (Amersham, Buckinghamshire, UK) by the  
15 method of Southern (Sambrook et al., 1989), and cross-linked with UV light. Filters were pre-hybridised and hybridised in 0.25 M Na<sub>2</sub>HPO<sub>4</sub> (pH=7.2), 1% BSA, 1mM EDTA, 7% SDS for 1 h and 4 h, respectively, and washed for 15 min in 5xSSC, 0.1% SDS; followed by 15 min in 2xSSC, 0.1% SDS; and 15 in 1xSSC, 0.1% SDS, at the hybridisation temperature. The temperature was 55°C for probing with a PCR  
20 fragment obtained by amplification using the primers Y9 (SEQ ID NO: 7) and Y7R (SEQ ID NO: 6) (see above) [ $\alpha$ -<sup>32</sup>P]dATP (Amersham, Buckinghamshire, UK), radio-labeled by random primer technique.

There was no hybridization with either the DNA from the relapsing fever *Borrelia*  
25 species, *B. hermsii*, *B. crocidurae*, nor the avian borreliosis agent *B. anserina* (Figure 6).

Furthermore, the P13 protein gene being localised to the chromosome of borreliae shows a higher degree of conservation among Lyme disease associated borreliae  
30 contrary to the plasmid-encoded major outer surface proteins A, B, and C which exhibit a significant species and strain dependent genetic and antigenic polymorphism (Barbour 1986, Jonsson et al., 1992, Wilske et al., 1993).

## EXAMPLE 11

*Expression of the P13 protein from B. burgdorferi B31 in E. coli*

## 5 11.1 Expression of full-length P13.

Two oligonucleotide primers, Y14 (SEQ ID NO: 12) and Y33 (SEQ ID NO: 15), were designed to anneal to the 5' end containing the lipidation signal and the 3' end of the P13 gene from *B. burgdorferi* B31. The primers contained *Bam*HI and *Eco*RI restriction sites, respectively, and were used to amplify the P13 gene in the PCR.

- 10 PCR amplification was performed using Ampli-Taq DNA polymerase (Perkin Elmer Cetus, Norwalk, CT). The PCR product was then treated with the mentioned restriction enzymes, purified by AGE and ligated in fusion with GST (glutathione S-transferase) into the *tac* promoter based expression vector pGEX-2T (Pharmacia, Uppsala, Sweden). The recombinant plasmid, designated pLY313F, was then used to trans-
- 15 form *E. coli* DH5 $\alpha$  cells. *E. coli* DH5 $\alpha$  cells containing the insert were grown and induced by adding isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) (Sigma, St. Louis, MO) to a final concentration of 1 mM to express the introduced P13 gene. The P13 gene product was subsequently identified by SDS-PAGE (Figure 7A) and Western blot with monoclonal antibody 15G6 against the P13 protein (Figure 7B).

20

## 11.2 Expression of truncated P13.

- A similar procedure was used to obtain a truncated variant, i.e. lacking the signal peptide. An oligonucleotide primer, Y13 (SEQ ID NO: 11), was designed to anneal to the 5' end without the lipidation signal sequence) of the P13 gene from *B. burgdor-*
- 25 *feri* B31. The primer also contains a *Bam*HI restriction site. The primer was used together with the primer Y33 (SEQ ID NO: 15) in a PCR reaction to amplify the part of the P13 gene without the DNA sequence encoding the signal sequence. A recombinant plasmid designated pLY313T was prepared, *E. coli* transformed and grown as described above. The truncated P13 gene product was subsequently identified by
- 30 SDS-PAGE (Figure 7A) and Western blot with monoclonal antibody 15G6 against the P13 protein (Figure 7B).

## EXAMPLE 12

## 35 DNA vaccination

## 12.1 Preparation of DNA constructs.

To enable expression of *B. burgdorferi* B31 P13 in mammalian cells, the natural leader sequence of the *P13* gene was replaced with the human tissue plasminogen activator

(hTPA) leader sequence and cloned into the expression vector VR1020 (Luke et al., 1997) to yield plasmid pLY-H (Figure 8A). A similar plasmid enabling the expression of *B. burgdorferi* B31 P13 in translational fusion with OspA was designed pLY-HA (Figure 8B).

5

More specifically, the DNA encoding TPA 5' UTR and leader peptide, P13 and OspA were isolated from previous plasmid constructs or amplified. In pLY-H the TPA signal was isolated from VR2210 (Luke et al., 1997) by digestion with *Pst*I/*Kpn*I. The *P13* gene was PCR amplified from pLY100 using the primers L1 (SEQ ID NO: 24) and L2  
10 (SEQ ID NO: 25). The *P13* containing fragment was digested with *Kpn*I/*Xba*I and introduced together with the *Pst*I/*Kpn*I isolated TPA signal into VR1020 digested with *Pst*I/*Xba*I.

In pLY-HA the TPA signal was PCR amplified with the primers L5 (SEQ ID NO: 28)  
15 and L6 (SEQ ID NO: 29). The *P13* gene was PCR amplified from pLY100 using the primers L3 (SEQ ID NO: 26) and L4 (SEQ ID NO: 27) The PCR fragments were digested with the appropriate restriction enzymes. The OspA gene was isolated from VR2210 by digestion with *Kpn*I/*Xba*I. All three fragments were combined in a three fragment ligation into the *Pst*I/*Xba*I digested VR1020 to yield pLY-HA.

20

### 12.2 Vaccination of mice.

Mice will be injected with the plasmids pLY-h and pLY-HA as well as a negative control plasmid not containing a coding sequence for a *Borrelia* antigen. The plasmid and control DNA are diluted in standard saline. Three bilateral injections of DNA will  
25 be given at two week intervals at a dosage of 50 µg/leg into the *rectus femoris* muscle.

### 12.3 Analysis of immune response.

Sera will be collected after each injection and analyzed by 1) antibody ELISA and 2)  
30 growth inhibition of spirochaetes.

#### 12.4 Challenge with Bb spirochaetes.

After the last injection, mice will be challenged with *B. burgdorferi sensu stricto* N40 spirochaetes (same OspA serogroup as B31). Spirochetes will be either injected intradermally in the tail or by the tick challenge model (Telford et al., 1993). Mice will be sacrificed following the challenge. Bladder, heart, plasma, and cross-cuttings of the tibiotarsal joints will be cultured in growth medium. Cultures will be examined for the presence of spirochaetes by phase-contrast microscopy and scored as negative if no spirochaetes are seen in 50 high-power fields.

#### 10 EXAMPLE 13

*Attempted cloning of the P13 gene encoding the 13 kDa protein using monoclonal antibodies.*

The clone pMG2 was obtained from Dr. Michael Norgard's laboratory. This clone had been isolated from a library prepared from partial *Sau3AI* digested DNA of *Borrelia burgdorferi* 297 cloned into the *Bam*HI site of the plasmid pGEX-1 (Pharmacia). The library had been screened with the monoclonal antibody 15G6. After IPTG induction of *E. coli* DH5 $\alpha$  cells transfected with the plasmid pMG2, a glutathione-S-transferase (GST) fusion protein reacting with the monoclonal antibody 15G6 could be seen in an immunoblot experiment. The fusion protein had a molecular weight of about 36 kDa, 26 kDa for the fusion partner GST plus 10 kDa for the Bb protein fragment.

According to restriction mapping, this clone contained an approximately 300 base pair insert. DNA sequencing showed an open reading frame of 251 bases. The insert was PCR amplified, oligolabelled, and used as a probe to screen libraries prepared from partial *Hind*III digested DNA from *B. burgdorferi* B31, *B. afzelii* ACA1, and *B. garinii* IP90, respectively.

Two positive clones were obtained from each *Borrelia* species and subsequently sequenced. A complete sequence determination was obtained from B31 and IP90 and a partial sequence was obtained from ACA1 (first half of the gene). The nucleotide sequences were found to encode a 27 kDa protein in size which did not coincide with the expected size of the 13 kDa protein from Bb.

35

Furthermore, in another expression experiment the expression in *E. coli* of IPTG induced pMG2 and the above mentioned Bb derived clones was studied using the monoclonal antibody 7D4. After induction *E. coli* transfected with all clones as well as the negative control produced two proteins reacting with the antibody, about 36

kDa and 26 kDa in size. These results indicate that the monoclonal antibody 7D4 did not specifically recognise the 13 kDa Bb protein but cross-reacted with other proteins produced by the *E.coli* cells under these conditions.

- 5 Later the identified 27 kDa protein has been verified to be encoded by supercoiled plasmids of Bb (Porcella et al., 1996).

#### EXAMPLE 14

##### 10 *Mass spectrometry analysis.*

Molecular weight determinations of P13 were performed on a VG Platform II mass spectrometer with a range of 2000 m/z equipped with an electrospray source (Micromass, Altrincham, UK). Prior to injection, the purified P13 preparation was  
15 precipitated with methanol:chloroform to remove any trace of SDS contamination. A P13 solution of 20 pmol/ml in water-acetonitrile (50:50 [vol/vol]) was mixed with 5% formic acid and introduced directly into the electrospray source at a flow rate of 5 ml/min. Calibration was performed by a separate introduction using horse heart myoglobin (16,951.5 Da). The MassLynx software was used to calculate the mole-  
20 cular weight.

The mass spectrometry analysis (Figure 9) indicated a molecular weight of 13.9 kDa compared to the deduced molecular weight of the mature (cleaved) P13 protein of 16.8 kDa but in good agreement with the observed molecular weight of the mature  
25 P13 protein of 13 kDa as determined by gel-electrophoresis.

In addition, the whole molecule mass spectrum detected two minor peptide populations increased with 267 Da increments from the major peak. These peptides probably represent further modified subsets of P13. Two possible post-translational  
30 modifications can be considered to generate the mass change of 267 Da. Stearoylation gives an average mass change of 266.5 Da while the addition of two pentoses generates a mass change of 264.2 Da.

## LIST OF REFERENCES

- EP-B-O 036 776
- EP-A-O 243 333
- 5 EP-A-O 366 238
- WO 88/01875
- WO 90/04411
- US Serial No. 08/373,455
- U.S. Patent No. 3,791,932
- 10 U.S. Patent No. 3,949,064
- U.S. Patent No. 4,174,384
- U.S. Patent No. 4,358,535
- U.S. Patent No. 4,554,101
- U.S. Patent No. 4,578,770
- 15 U.S. Patent No. 4,596,792
- U.S. Patent No. 4,599,230
- U.S. Patent No. 4,599,231
- U.S. Patent No. 4,601,903
- U.S. Patent No. 4,603,102
- 20 U.S. Patent No. 4,608,251
- U.S. Patent No. 5,411,732
- Adam T, Gassmann GS, Rasiah C, Göbel UB. 1991.** Phenotypic and genotypic analysis of *Borrelia burgdorferi* isolates from various sources. *Infection and Immunity*, 25 59: 2579-2585.
- Adelman JP, Hayflick JS, Vasser M, Seeburg PH. 1983.** In vitro deletional mutagenesis for bacterial production of the 20,000-dalton form of human pituitary growth hormone. *DNA*. 2(3):183-93.
- 30 **Anderson JF, Magnarelli LA, McAnich JB. 1988.** *Journal of Clinical Microbiology*, 26: 2209-2212.
- Arimitsu Y, Takashima I, Yoshii Z, Higashi Y, Kameyama S, Mizuguchi J. 1991.** 35 *Journal of Infectious Diseases*, 163: 682-683.

**Barbour AG, Tessier SL, Hayes SF. 1984.** Variation in a major surface protein of Lyme disease spirochaetes. *Infection and Immunity*, 45: 94-100.

10

Zbl Bakt Hyg, 263: 83-91.

15

infected with *Borrelia burgdorferi*. Infection and Immunity, 61: 4696-4702.

**Bergström S, Sjöstedt A, Dotevall L, Kaijser B, Ekstrand-Hammarström B, Wallberg C, Skogman G, Barbour AG. 1991.** Diagnosis of Lyme borreliosis by an enzyme immunoassay detecting immunoglobulin G reactive to purified *Borrelia burgdorferi* cell components. *European Journal of Clinical Microbiology and Infectious Diseases*, 10: 422-427.

**Beaucage SL, Caruthers MM et al., 1981. Tetrahedron Letters, 22: 1859-1862.**

30

disease - a tick borne spirochetosis? *Science*, 216: 1317-1319.

**Burman N, Bergström S, Restrepo BI, Barbour AG. 1990.** The variable antigens Vmp7 and Vmp21 of the relapsing fever bacterium *Borrelia hermsii* are structurally analogous to the VSG proteins of the African trypanosome. *Molecular Microbiology*, 4: 1715-1726.

5

**Canica MM, Nato F, duMerle L, Mazie JC, Baranton G, Postic D. 1993.** Monoclonal antibodies for identification of *Borrelia afzelii* sp. nov. associated with late cutaneous manifestations of Lyme borreliosis. *Scandinavian Journal of Infectious Diseases*, 25: 441-448.

10

**Chang AC, Nunberg JH, Kaufman RJ, Erlich HA, Schimke RT, Cohen SN. 1978.** Phenotypic expression in *E. coli* of a DNA sequence coding for mousedihydrofolate reductase. *Nature*. 275(5681):617-24,

15 **Craft JE, Grodzicki RL, Steere AC. 1984.** Antibody response in Lyme disease: evaluation of diagnostic tests. *Journal of Infectious Diseases*, 149: 789-795.

**Crea R, Kraszewski A, Hirose T, Itakura K. 1978.** Chemical synthesis of genes for human insulin. *Proceedings of the National Academy of Sciences USA*. 75(12):5765-20 5769.

**Eichenlaub R. 1979.** Mutants of the mini-F plasmid pML31 thermosensitive in replication. *Journal of Bacteriology*, 138: 559-566.

25 **Erdile LF, Brandt M-N, Warakowski DJ, Westrack GJ, Sadziene A, Barbour AG, Mays JP. 1993.** Role of attached lipid in immunogenicity of *Borrelia burgdorferi* OspA. *Infection and Immunity*, 61: 81-90.

**Ferdows MS, Barbour AG. 1989.** Megabase-sized linear DNA in the bacterium  
30 *Borrelia burgdorferi*, the Lyme disease agent. *Proceedings of National Academy of Science*, 86: 5969-5973.

**Fiers W, Contreras R, Haegemann G, Rogiers R, Van de Voorde A, Van Heuverswyn H, Van Herreweghe J, Volckaert G, Ysebaert M. 1978.** Complete nucleotide  
35 sequence of SV40 DNA. *Nature*. 273(5658):113-20.



- Fikrig E, Barthold SW, Marcantonio N, DePonte K, Kantor FS, Flavell RA. 1992.** Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. *Infection and Immunity*, 60: 657-661.
- 5 **Fikrig E, Barthold SW, Persing DH, Sun X, Kantor FS, Flavell RA. 1992.** *Borrelia burgdorferi* strain 25015: characterization of outer surface protein A and vaccination against infection. *Journal of Immunology*, 148: 2256-2260.
- Fraser CM, Casjens S, Huang WM, Sutton GG, Clayton R, Lathigra R, White O,**  
10 **Ketchum KA, Dodson R, Hikey EK, Gwinn M, Doughery B, Tomb JF, Fleischmann RD, Richardson D, Peterson J, Kervalage AR, Quackenbush J, Salzberg S, Hanson M, van Vugt R, Palmer N, Adams MD, Gocayne J, Venter JC et al., 1997.** Genomic sequence of a Lyme diseases spirochaete, *Borrelia burgdorferi*. *Nature*, 390: 580-586.
- 15 **Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, Yansura DG, Ross MJ, Miozzari G, Crea R, Seeburg PH. 1979.** Direct expression in *Escherichiacoli* of a DNA sequence coding for human growth hormone. *Nature*. 281(5732):544-548.
- 20 **Goodman JL, Jarkovich P, Kramber JM, Johnson RC. 1991.** Molecular detection of persistent *Borrelia burgdorferi* in the urine of patients with active Lyme disease. *Infection and Immunity*, 59: 269-278.
- Hess et al., 1968.** *Advances in Enzyme Regulation*, 7: 149-166.
- 25 **Hitzeman RA, Clarke L, Carbon J. 1980.** Isolation and characterization of the yeast 3-phP13 oglycerokinase gene (PGK) by an immunological screening technique. *Journal of Biological Chemistry*. 255(24):12073-12080.
- 30 **Holland MJ, Holland JP. 1978.** Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceraldehyde-3-phP13 ate dehydrogenase, and phP13 oglycerate kinase. *Biochemistry*. 17(23):4900-4907.
- Honarvar N, Schaible UE, Galanos C, Wallich R and Simon MM. 1994.** A 14,000  
35 MW lipoprotein and a glycolipid-like structure of *Borrelia burgdorferi* induce

proliferation and immunoglobulin production in mouse B cells at high frequencies. Immunology 82: 389-396.

Hopp TP, Woods KR. 1981. Proceedings of the National Academy of Sciences USA, 5 78:3824-3828.

Itakura K, Hirose T, Crea R, Riggs AD, Heyneker HL, Bolivar F, Boyer HW. 1977. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science. 198(4321):1056-63,

10

Jameson BA, Wolf H. 1988. Computer Applications in the biosciences, 4:181-186.

Jones EW. 1977. Proteinase mutants of Saccharomyces cerevisiae. Genetics, 85(1):23-33.

15

Jonsson M, Noppa L, Barbour AG, Bergström S. 1992. Heterogeneity of outer membrane proteins in *Borrelia burgdorferi*: comparison of *osp* operons of three isolates of different geographic origins. Infection and Immunity, 60: 1845-1853.

20 Katona LI, Beck G and Habicht GS. 1992. Purification and immunological characterization of a major low-molecular-weight lipoprotein from *Borrelia burgdorferi*. Infect. Immun., 60: 4995-5003.

Kingsman AJ, Clarke L, Mortimer RK, Carbon J. 1979. Replication in Saccharomyces 25 cerevisiae of plasmid pBR313 carrying DNA from the yeast *trp1* region. Gene. 7(2):141-52.

Kryucheynikov VN, Korenberg EI, Scherbakov SV, Kovalevsky YV, Levin ML. 1988. Identification of *Borrelia* isolated in the USSR from *Ixodes persulcatus schulze* ticks. 30 Journal of Microbiology, Epidemiology and Immunobiology, 12: 41-44.

Kyte J, Doolittle RF. 1982. Journal of Molecular Biology, 157:105-132.

Laemmli UK. 1970. Nature 227:680-685

35

**Lebech AM, Hindersson P, Vuust J, Hansen KJ. 1991.** Comparison of in vitro culture and polymerase chain reaction for detection of *Borrelia burgdorferi* in tissue from experimentally infected animals. *Journal of Clinical Microbiology*, 29: 731-737.

- 5 **Luke CJ, Carner K, Liang X, Barbour AG. 1997.** An OspA-based DNA Vaccine protects mice against infection with *Borrelia burgdorferi*. *The Journal of Infectious Diseases*, 175:91-97.

- Magnarelli LA., Anderson JF, Barbour AG. 1989.** Enzyme-linked immunosorbent  
10 assays for Lyme disease: reactivity of subunits of *Borrelia burgdorferi*. Cross-reactivity in serologic tests for Lyme disease and other spirochetal infections. *Journal of Infectious Diseases*, 159: 43-49.

- Marconi RT, Garon CF. 1992.** Phylogenetic analysis of the genus *Borrelia*: a  
15 comparison of North American and European isolates of *Borrelia burgdorferi*. *Journal of Bacteriology*, 174: 241-244.

- Marconi RT, Konkel ME, Garon CF. 1993.** Variability of *osp* genes and gene products among species of Lyme disease spirochaetes. *Infection and Immunity*, 61: 2611-  
20 2617.

**Marconi RT, Samuels DS, Schwan TG, Garon CF. 1993.** Identification of a protein in several *Borrelia* species which is related to OspC of Lyme disease spirochaetes. *Journal of Clinical Microbiology*, 31: 2577-2583.

25

**Matsudaira P. 1987.** Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. *Journal of Biological Chemistry*, 262: 10035-10038.

- 30 **Messing et al., 1981.** Third Cleveland Symposium on Macromolecules and Recombinant DNA, Ed. A Walton, Elsevier, Amsterdam.

- Nielsen PE, Egholm M, Berg RH, Buchardt O. 1991.** Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. *Science*, 254:  
35 1497-1500.

- Norris SJ, Carter CJ, Howell JK, Barbour AG. 1992.** Low-passage-associated proteins of *Borrelia burgdorferi* B31: Characterization and molecular cloning of OspD, a surface exposed, plasmid-encoded lipoprotein. *Infection and Immunity*, 60: 4662-4672.
- 5 **Norton Hughes CA, Engstrom SM, Coleman LA, Kodner CB, Johnson RC. 1993.** Protective immunity is induced by a *Borrelia burgdorferi* mutant that lacks OspA and OspB. *Infection and Immunity*, 61: 5115-5122.
- Porcella SF; Popova TG, Akins DR, Li M, Radolf JD, Norgard MV. 1996.** *Borrelia*  
10 *burgdorferi* supercoiled plasmids encode multicopy tandem reading frames and a lipoprotein gene family. *Journal of Bacteriology*. 178: 3293-3307.
- Rahn DW, Malavista SE. 1991.** *Annals of Internal Medicine*, 114: 472-481.
- 15 **Remington: The Science and Practice of Pharmacy, 19<sup>th</sup> ed., Gennaro, AR, 1995.**
- Rosa PA, Schwan TG. 1989.** A specific and sensitive assay for the Lyme disease spirochaete *Borrelia burgdorferi* using the polymerase chain reaction. *Journal of Infectious Diseases*, 160:1018-1029.
- 20 **Šadziene A, Thompson PA, Barbour AG. 1993.** In vitro inhibition of *Borrelia burgdorferi* growth by antibodies. *Journal of Infectious Diseases*, 167: 165-172.
- Šadziene A, Thomas DD and Barbour AG. 1994.** *Borrelia burgdorferi* mutant lacking  
25 Osp: Biological and immunological characterization. *Infection and Immunity*, 63: 1573-1580.
- Sambri V, Moroni A, Massaria F, Brocchi E, De Simone F and Cevenini R. 1991.** Immunological characterization of a low molecular mass polypeptidic antigen of  
30 *Borrelia burgdorferi*. *FEMS Microb. Immunol.* 76: 345-350
- Sambrook J, Fritsch EF, Maniatis T. 1989.** *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- 35 **Schaible UE, Kramer MD, Eichmann K, Modolell M, Museteanu C, Simon MM. 1990.** Monoclonal antibodies specific for the outer surface protein A (OspA) of *Borrelia*

burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proceedings of the National Academy of Sciences USA 87: 3768-72.

**Schmid GP. 1985.** Reviews of infectious diseases, 7: 41-49.

5

**Shanafelt MC, Hinderson P, Soderberg C, Mensi N, Turck CW, Webb D, Yssel H, Peltz G. 1991.** T cell and antibody reactivity with the *Borrelia burgdorferi* 60-kDa heat shock protein in Lyme arthritis. Journal of Immunology, 146: 3985-3992.

10 **Siebenlist U, Simpson RB, Gilbert W. 1980.** E. coli RNA polymerase interacts homologously with two different promoters. Cell. 20(2):269-281.

**Steere AC, Malavista SE, Syndman DR. 1977.** Arthritis and reuhmatism, 20: 7-17.

15 **Steere AC, Taylor E, Wilson ML, Levine JF, Spielman A. 1986.** Journal of Infectious Diseases, 154: 295-300.

**Stinchcomb DT, Struhl K, Davis RW. 1979.** Isolation and characterisation of a yeast chromosomal replicator. Nature. 282(5734):39-43.

20

**Telford SR, Fikrig E, Barthold SW, Rosa Brunet L, Spielman A, Flavell RA. 1993.** Protection against antigenically variable *Borrelia burgdorferi* conferred by recombinant vaccines. Journal of Experimental Medicine, 178: 755-758.

25 **Tschumper G, Carbon J. 1980.** Sequence of a yeast DNA fragment containing a chromosomal replicator and the TRP1 gene. Gene. 10(2):157-66.

**Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A. et al., 1993.** Heterologous protection against  
30 influenza by injection of DNA encoding a viral protein. Science. 259(5102):1745-1749.

**von Heijne G. 1986.** A new method for predicting signal sequences cleavage sites. Nucleic Acid Research, 11: 4683-4690.

35

- Wallich R, Moter SE, Simon MM, Ebnet K, Heiberger A, Kramer MD. 1990. The *Borrelia burgdorferi* flagellum-associated 41-kilodalton antigen (flagellin): molecular cloning, expression, and amplification of the gene. *Infection and Immunity*, 58: 1711-1719.
- 5
- Wilske B, Preac-Mursic V, Jauris S, Hofman A, Pradel I, Soutschek E, Schwab E, Will G, Wanner G. 1993. Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of *Borrelia burgdorferi*. *Infection and Immunity*, 61: 2182-2191.
- 10
- Zingg BC, Anderson JF, Johnson RC, LeFebvre RB. 1993. Comparative analysis of genetic variability among *Borrelia burgdorferi* isolates from Europe and the United States by restriction enzyme analysis, gene restriction fragment length polymorphism, and pulse-field gel electrophoresis. *Journal of Clinical Microbiology*, 31: 3115-3122.
- 15
- Åsbrink E, Hovmark A, Hederstedt B. 1984. The spirochetal etiology of acrodermatitis chronica atrophicans Herxheimer. *Acta Dermatologica et Venereologica*, 64: 506-512.

## CLAIMS

1. An isolated nucleic acid fragment which
- 5 - encodes a polypeptide fragment which exhibits a substantial immunological reactivity with a rabbit polyclonal antibody raised against a polypeptide having an apparent molecular weight of 13 kDa as determined by SDS-PAGE followed by visualization, said polypeptide being derived from *Borrelia burgdorferi* B313 and being encoded by the nucleotide sequence of SEQ ID NO: 18, said rabbit polyclonal antibody exhibiting substantially no immunological reactivity with proteins
- 10 - from at least 95% of spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*, and/or
- 15 - hybridises readily under highly stringent hybridization conditions with a DNA fragment having a nucleotide sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, or with a DNA fragment complementary thereto, but exhibits no substantial hybridization when the hybridization conditions are highly stringent with genomic DNA from at least 95% of
- 20 - spirochaetes randomly selected from the group consisting of *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*.
2. The nucleic acid fragment according to claim 1, which encodes a polypeptide fragment comprising an amino acid sequence comprised in a polypeptide, said polypeptide
- 25 - being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, and/or *Borrelia afzelii* ACAI but being substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, or *Borrelia hispanica*.
- 30 3. The nucleic acid fragment according to claim 1 or 2, which encodes a polypeptide fragment comprising at least a part of an amino acid sequence of a protein having an apparent molecular weight of 13 kDa, said protein being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, and/or *Borrelia afzelii* ACAI but being substantially absent from whole cell

preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*.

4. The nucleic acid fragment according to any of the preceding claims, which encodes  
5 a polypeptide fragment comprising at least one epitope, said epitope being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI but being substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*.

10

5. The nucleic acid fragment according to any of the preceding claims, which encodes a polypeptide fragment comprising at least one epitope of a protein having an apparent molecular weight of 13 kDa, said protein being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia*  
15 *afzelii* ACAI but being substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*.

6. The nucleic acid fragment according to any of the preceding claims, which encodes  
20 a polypeptide fragment which has an amino acid sequence exhibiting a sequence identity of at least 50% with SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23, or with subsequences thereof having a length of at least 10 amino acid residues.

7. The nucleic acid fragment according to any of the preceding claims, wherein the  
25 nucleotide sequence has a sequence homology of at least 70% with SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22, or with subsequences thereof having a length of at least 12 nucleotides.

8. A nucleic acid fragment according to any of the preceding claims, which comprises  
30 a nucleic acid fragment encoding a polypeptide fragment which comprises at least one amino acid sequence selected from the group consisting of amino acid residues 19-27, 33-36, 41-47, 95-104, 138-147 and 174-179 in SEQ ID NO: 19; amino acid residues 19-26, 32-35, 40-47, 94-101, 137-146, and 174-178 in SEQ ID NO: 21; and amino acid residues 18-26, 30-33, 39-46, 91-104, 137-145 and 173-177 in SEQ ID NO: 23.



9. The nucleic acid fragment according to any of the preceding claims, which encodes a protein having an apparent molecular weight of 13 kDa which is present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI but which is substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*.
10. The nucleic acid fragment according to claim 9, wherein the encoded protein is present in fraction B from *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI.
11. The nucleic acid fragment according to claim 10, wherein the encoded protein is a surface exposed protein of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI.
12. A nucleic acid fragment according to any of the preceding claims which comprises a nucleotide sequence encoding a polypeptide fragment which includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 21, and 23.
13. A nucleic acid fragment according to any of the preceding claims, which comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 18, 20, and 22.
14. A nucleic acid fragment according to claim 12 which consists of a nucleotide sequence encoding a polypeptide fragment consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 21, and 23.
15. A nucleic acid fragment according to claim 13, which consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 18, 20, and 22.
16. A nucleic acid fragment according to any of claims 1-13, which encodes a fusion polypeptide.

17. The nucleic acid fragment according to claim 16, which encodes a fusion polypeptide which comprises, as a fusion partner, a polypeptide fragment which enhances the immunogenicity of the fusion polypeptide relative to the immunogenicity of a polypeptide not comprising said second fusion partner or which facilitates the expression  
5 of the fusion polypeptide in a host cell and/or the subsequent purification of the polypeptide.

18. The nucleic acid fragment according to claim 16 or 17, which encodes a fusion polypeptide comprising, as a fusion partner, a polypeptide fragment which
- 10
- has the same amino acid sequence as at least one amino acid sequence selected from the group consisting of amino acid residues 19-27, 33-36, 41-47, 95-104, 138-147 and 174-179 in SEQ ID NO: 19; amino acid residues 19-26, 32-35, 40-47, 94-101, 137-146, and 174-178 in SEQ ID NO: 21; and amino acid  
15 residues 18-26, 30-33, 39-46, 91-104, 137-145 and 173-177 in SEQ ID NO: 23,
  - is a lipoprotein selected from the outer membrane lipoprotein from *E. coli* and OspA from *Borrelia burgdorferi sensu lato*,
  - is a viral protein selected from Hepatitis B surface antigen, Hepatitis B core antigen, and the influenza virus non-structural protein NS1,
  - is an immunoglobulin binding protein selected from protein A, protein G, and the  
20 ZZ-peptide,
  - is a T-cell epitope,
  - is a B-cell epitope,
  - is a bacterial fimbrial protein selected from the pilus components pilin and papA,  
25 and/or
- 30

- is the maltose binding protein, glutathione S-transferase,  $\beta$ -galactosidase, calmodulin binding protein or poly-histidine.

19. The nucleic acid fragment according to any of the preceding claims, which is a  
5 DNA fragment.

20. A polypeptide fragment which exhibits a substantial immunological reactivity with a polyclonal rabbit antibody raised against a polypeptide having an apparent molecular weight of 13 kDa as determined by SDS PAGE followed by visualization and being  
10 derived from *Borrelia burgdorferi* B313, said polypeptide comprising the amino acid sequence 1-167 of SEQ ID NO: 19, said polyclonal rabbit antibody exhibiting substantially no immunological reactivity with whole cell preparations from at least 95% of randomly selected *B. hermsii*, *B. crocidurae*, *B. anserina*, or *B. hispanica*, with the proviso that said polypeptide is essentially free from other *Borrelia*-derived antigens  
15 when it is identical in amino acid sequence to a 13 kDa surface exposed polypeptide which can be extracted from *Borrelia burgdorferi sensu lato*,

the polypeptide fragment optionally being lipidated.

20 21. The polypeptide fragment according to claim 20, which comprises an amino acid sequence comprised in a polypeptide, said polypeptide being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI but being substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*,  
25 *Borrelia anserina*, or *Borrelia hispanica*.

22. The polypeptide fragment according claim 20 or 21, which comprises at least a part of the amino acid sequence of a protein having an apparent molecular weight of 13 kDa, said protein being present in whole cell preparations of *Borrelia burgdorferi*  
30 B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI but being substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*.

23. A polypeptide fragment according to any of claims 20-22, which comprises at least one epitope, said epitope being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI but being substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*.

24. A polypeptide fragment according to any of claims 20-23, which comprises at least one epitope of a protein having an apparent molecular weight of 13 kDa, said protein being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI but being substantially absent from whole cell preparations of at least 95% of randomly selected *Borrelia hermsii*, *Borrelia crocidurae*, *Borrelia anserina*, and *Borrelia hispanica*.

25. The polypeptide fragment according to claim any of claims 20-24, which comprises at least one amino acid sequence selected from the group consisting of amino acid residues 19-27, 33-36, 41-47, 95-104, 138-147 and 174-179 in SEQ ID NO: 19; amino acid residues 19-26, 32-35, 40-47, 94-101, 137-146, and 174-178 in SEQ ID NO: 21; and amino acid residues 18-26, 30-33, 39-46, 91-104, 137-145 and 173-177 in SEQ ID NO: 23.

26. The polypeptide fragment according to any of claims 20-25, which has an amino acid sequence identical to that of a protein having an apparent molecular weight of 13 kDa and being present in whole cell preparations of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI.

27. The polypeptide fragment according to claim 26, wherein the protein is present in fraction B from *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI.

28. The polypeptide fragment according to claim 26 or 27, wherein the protein is a surface exposed protein of *Borrelia burgdorferi* B31, *Borrelia burgdorferi* B313, *Borrelia garinii* IP90, or *Borrelia afzelii* ACAI.

29. The polypeptide fragment according to any of claims 20-28, which has an amino acid sequence exhibiting a sequence identity of at least 50% with an amino acid sequence selected from SEQ ID NOs: 19, 21, and 23, or with a subsequence thereof of at least 10 amino acids.

5

30. A polypeptide fragment according to any of claims 20-29, which is encoded by a nucleotide sequence exhibiting a sequence identity of at least 70% with a sequence selected from the group consisting of SEQ ID NOs: 18, 20, and 22, or with a subsequence thereof of at least 12 nucleotides.

10

31. The polypeptide fragment according to claim 29, which comprises an amino acid sequence selected from SEQ ID NOs: 19, 21, and 23.

32. The polypeptide fragment according to claim 31, which is encoded by a DNA fragment comprising a nucleotide sequence selected from SEQ ID NOs: 18, 20, and 22.

15

33. A fusion polypeptide comprising as a first fusion partner the polypeptide according to any of claims 20-32.

34. The fusion polypeptide according to claim 33, which comprises, as a second fusion partner, a polypeptide fragment which enhances the immunogenicity of the fusion polypeptide relative to the immunogenicity of a polypeptide not comprising said second fusion partner or which facilitates the expression of the fusion polypeptide in a host cell and/or the subsequent purification of the polypeptide.

20

35. The fusion polypeptide according to claim 33 or 34, wherein at least one second fusion partner is a polypeptide

25

- which has the same amino acid sequence as at least one amino acid sequence selected from the group consisting of amino acid residues 19-27, 33-36, 41-47, 95-104, 138-147 and 174-179 in SEQ ID NO: 19; amino acid residues 19-26, 32-35, 40-47, 94-101, 137-146, and 174-178 in SEQ ID NO: 21; and amino acid residues 18-26, 30-33, 39-46, 91-104, 137-145 and 173-177 in SEQ ID NO: 23,

30

- which is a lipoprotein selected from the outer membrane lipoprotein from *E. coli* and OspA from *Borrelia burgdorferi sensu lato*,
  - 5 - which is a viral protein selected from Hepatitis B surface antigen, Hepatitis B core antigen, and the influenza virus non-structural protein NS1,
  - which is an immunoglobulin binding protein selected from protein A, protein G, and the synthetic ZZ-peptide,
  - 10 - which is a T-cell epitope,
  - which is a B-cell epitope,
  - 15 - which is a bacterial fimbrial protein selected from the pilus components pilin and papA, and/or
  - which is the maltose binding protein, glutathione S-transferase,  $\beta$ -galactosidase, or poly-histidine.
  - 20
36. A non-borrelial vector carrying the nucleic acid fragment according to any of claims 1-19.
37. The vector according to claim 36, which is capable of autonomous replication.
- 25
38. The vector according to claim 36, which is selected from the group consisting of a plasmid, a phage, a cosmid, a mini-chromosome, and a virus.
39. A vector according to any of claims 36-38, which, when introduced in a host cell,
- 30
- is integrated in the host cell genome.
40. A vector according to any of claims 36-39, wherein the vector comprises, in the 5'→3' direction and in operable linkage, a promoter for driving expression of the nucleic acid fragment according to any of claims 1-19, a nucleic acid sequence

encoding a leader peptide enabling secretion of or integration into the membrane of the polypeptide fragment, the nucleic acid fragment according to any of claims 1-19, and a nucleic acid sequence encoding a terminator.

- 5 41. A vector according to claim 40, wherein the promoter drives expression in a eukaryotic cell.

42. A vector according to claim 40 or 41, wherein the leader peptide enables secretion from or integration into the membrane of a mammalian cell.

10

43. A transformed cell carrying the vector of any of claims 36-42 and capable of replicating the nucleic acid fragment according to any of claims 1-19.

44. A transformed cell according to claim 43, which is a microorganism selected from  
15 a bacterium, a yeast, a protozoan, or a cell derived from a multicellular organism selected from a fungus, an insect cell, a plant cell, and a mammalian cell.

45. A transformed cell according to claim 44 which is a bacterium of the genus *Escherichia*, *Bacillus* or *Salmonella*.

20

46. A transformed cell according to claim 45, which is an *E. coli* cell.

47. A stable cell line producing the polypeptide according to any of claims 20-35, which carries the vector according to any of claims 36-42 and which expresses the  
25 nucleic acid fragment according to any of claims 1-19.

48. A method of preparing a polypeptide fragment as defined in any of claims 1-19, the method comprising

- 30 - culturing the transformed cell according to any of claims 43-46 or the stable cell line according to claim 47 under conditions facilitating the expression of the polypeptide fragment thereby, and

- harvesting the polypeptide fragment, and optionally subjecting the polypeptide to post-translational modification(s);

or

5

- synthesising the polypeptide fragment by solid-phase peptide synthesis or by liquid-phase peptide synthesis.

49. A method according to claim 48, wherein the post-translational modifications  
10 involve lipidation, glycosylation, cleavage and/or elongation.

50. A vaccine comprising an amount of the polypeptide fragment according to any of  
claims 20-35 or of the polypeptide fragment prepared by the method according to  
claim 48 or 49, the amount of the polypeptide fragment being effective to confer sub-  
15 stantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in an  
animal, including a human being, the polypeptide fragment being formulated in com-  
bination with a pharmaceutically acceptable carrier, diluent or vehicle, and the vaccine  
optionally further comprising an adjuvant.

20 51. A vaccine according to claim 50, wherein the pharmaceutically acceptable carrier,  
vehicle, or diluent is selected from the group consisting of sterile water, physiological  
saline, glucose, polyalkylene glycols, and triglycerides; and wherein the adjuvant is  
selected from the group consisting of aluminium hydroxide or phosphate (alum),  
synthetic polymers of sugars (Carbopol), bacterial cells such as *C. parvum* or endo-  
25 toxins or lipopolysaccharide components of gram-negative bacteria, physiologically  
acceptable oil vehicles such as mannide mono-oleate (Aracel A), a perfluorocarbon  
(Fluosol-DA).

52. A vaccine according to claim 50 or 51, wherein the amount of the polypeptide  
30 fragment is in the range of 1-1000 µg per dose unit, such as between 2 and 750 µg,  
between 5 and 500 µg, between 7.5 and 250 µg, between 10 and 150 µg, between  
10 and 100 µg, between 10 and 75 µg, and between 10 and 50 µg.



53. A live vaccine comprising a non-pathogenic microorganism carrying and being capable of expressing the nucleic acid fragment according to any of claims 1-19 so as to produce the polypeptide fragment according to any of claims 20-35, the live vaccine being effective in conferring increased resistance to infection with *Borrelia burgdorferi sensu lato* in an animal, including a human being.

54. The live vaccine according to claim 53, wherein the non-pathogenic microorganism is selected from the group consisting of *Mycobacterium bovis* BCG, *Salmonella typhi*, *Salmonella typhimurium*, *Salmonella paratyphi*, *Staphylococcus aureus*, and *Listeria monocytogenes*.

55. A combination vaccine comprising

an amount of the polypeptide fragment according to any of claims 20-35 or of the polypeptide fragment prepared by the method according to claim 48 or 49, the amount of the polypeptide fragment being effective to confer substantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in an animal, including a human being;

and

at least one further *Borrelia* antigen,

the polypeptide fragment and the antigen being formulated in combination with a pharmaceutically acceptable carrier, vehicle, or diluent and the vaccine optionally further comprising an adjuvant.

56. A combination vaccine according to claim 55, wherein the at least one further *Borrelia* antigen is selected from the group consisting of OspA, OspB, OspC, OspD, OspE, OspF, OspG, PC, Oms28, Oms45, Oms 66, decorin binding protein (dbp), LpLA7, EppA, T5, S1, 26 kDa, 39 kDa, 66 kDa, 79 kDa, 85 kDa, and 110 kDa antigen.

57. A combination vaccine comprising at least two non-identical polypeptide fragments according to any of claims 20-35 or at least two non-identical polypeptide fragments prepared by the method according to claim 48 or 49, the vaccine comprising an amount of the polypeptide fragments effective to confer substantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in an animal, including a human being, in combination with a pharmaceutically acceptable carrier, vehicle, or diluent, the vaccine optionally further comprising an adjuvant.

58. A vaccine comprising the nucleic acid fragment according to any of claims 1-19 or a vector according to any of claims 36-42, the vaccine effecting *in vivo* expression of antigens by an animal, including a human being, to whom the vaccine has been administered, the amount of expressed antigens being effective to confer substantially increased resistance to infections with *Borrelia burgdorferi sensu lato* in an animal, including a human being.

59. A diagnostic composition adapted for the determination of *Borrelia burgdorferi sensu lato* in a sample, the composition comprising the polypeptide fragment according to any of claims 20-35 or the polypeptide fragment prepared by the method according to claim 48 or 49, the amount of the polypeptide fragment being effective to detectably react with antibodies present in the sample, the antibodies being directed against *Borrelia burgdorferi sensu lato*, the composition optionally comprising a detectable label.

60. A diagnostic composition adapted for the determination of *Borrelia burgdorferi sensu lato* in a sample, the composition comprising an amount of the nucleic acid fragment according to any of claims 1-19 which is effective to detectably bind to a nucleic acid fragment from *Borrelia burgdorferi sensu lato* present in the sample, the composition optionally comprising a detectable label.

61. A method of immunizing an animal, including a human being, against infections with *Borrelia burgdorferi sensu lato*, the method comprising administering to the animal an immunogenically effective amount of the vaccine according to any of claims 50-58.

62. A method of determining the presence of antibodies directed against *Borrelia burgdorferi sensu lato* in a sample, comprising incubating the sample with the polypeptide fragment according to any of claims 20-35 or with the polypeptide fragment prepared by the method according to claim 48 or 49, and detecting the presence of  
5 bound antibody resulting from the administration or incubation.

63. A method of determining the presence of *Borrelia burgdorferi sensu lato* nucleic acids in a sample, comprising incubating the sample with the nucleic acid fragment according to any of claims 1-19, and detecting the presence of hybridized nucleic  
10 acids resulting from the incubation.

64. A method for determining the presence of *Borrelia burgdorferi sensu lato* nucleic acids in a sample, comprising subjecting the nucleic acid fragment according to any of claims 1-19 to a molecular amplification reaction, such as PCR, and detecting the  
15 presence of amplified nucleic acid which is specific for *Borrelia burgdorferi sensu lato*.

65. A diagnostic kit comprising


- a polypeptide fragment according to any of claims 20-35 and a means for  
20 detecting the the polypeptide fragment with antibody bound thereto,
- a nucleic acid fragment according to any of claims 1-19 and a means for  
detecting the binding between the nucleic acid fragment and nucleic acid bound  
thereto, or  
25
- a set of nucleic acid primers which, when used in a molecular amplification procedure together with the nucleic acid fragment according to any of claims 1-19, will result in specific amplification of said nucleic acid fragment, and a means for  
detecting the amplified nucleic acid fragment.

30

66. A method for the preparation of an immunological composition such as a vaccine, the method comprising the steps of admixing


- an adjuvant.

Fig. 1A

[illegible]

2/16


Fig. 1B




0007ED 24420560

3/16

Fig. 1C



**Fig. 2A**



*B. Burgdorferi* B31


Variable	Mean	SD	Min	Max
Age	35.5	10.5	18	65
Gender	0.5	0.5	0	1
Marital status	0.5	0.5	0	1
Education	12.5	1.5	9	16
Income	1500	500	500	3000
Health status	0.5	0.5	0	1
Smoking status	0.5	0.5	0	1
Alcohol consumption	0.5	0.5	0	1
Exercise frequency	0.5	0.5	0	1
Stress level	0.5	0.5	0	1
Sleep quality	0.5	0.5	0	1
Work satisfaction	0.5	0.5	0	1
Life satisfaction	0.5	0.5	0	1
Depression score	10	10	0	30
Anxiety score	10	10	0	30
Quality of life score	50	10	30	70





6/16

Fig. 3A




00070" / 2420560

7/16

Fig. 3B

IP90 ACA1 B31  
BF BF BF



COATED "2420560"

00070" 24420360

8/16

Fig. 4A




Fig. 4 B






Fig. 4 C



9/16


Fig. 5A



000760 09/508487

10/16

Fig. 5B




09/508487 "WO 99/12960"

11/16

Fig. 6


*B. burgdorferi*  
*B. hermsii*  
*B. crocidurae*  
*B. anserina*



000707/2420560

12/16

Fig. 7A




00070 28420560



13/16

Fig. 7B



14/16

Fig. 8A

pLY-H






Fig. 8B



16/16

Fig. 9



FROMMER LAWRENCE & HAUG, LLP  
File No.: 454312-3150

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor (if plural, names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention

### P13 ANTIGENS FROM BORRELIA:

the specification of which:

X is attached hereto  
X was filed with/transmitted to USPTO on \_\_\_\_\_ as:  
X United States Application Serial No. \_\_\_\_\_  
X as the National Phase or Continuation or Continuation-in-Part of PCT  
 Application No. PCT/IB98/01424, filed September 4, 1998  
 designating the U.S., and published as WO 99/12960 on March 18,  
1999,  
X with amendments through the date even herewith (if applicable, give details).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119 (a) - (d) or § 365 (b) of any foreign application(s) for patent or inventor's certificate, or § 365 (a) of any PCT International application(s) designating at least one country other than the United State of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT International applications designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign/PCT Application(s) [list additional applications on separate page]:

<u>Country (or PCT)</u>	<u>Application Number:</u>	<u>Filed (Day/Month/Year)</u>	<u>Priority Claimed:</u>	
Denmark	DK 1041/97	10/September/1997	<u>Yes</u>	<u>No</u>
			X	

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s) or § 365 (c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior United States or PCT International application(s) in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. (or U.S.-designating PCT) Application(s) [list additional applications on separate page]:  
U.S. Serial No.: Filed (Day/Month/Year) PCT Application No. Status (patented, pending, abandoned)

09/153,447	15/September/1998	Pending
	4/September/1998	PCT/IB98/01424


I hereby appoint William S. Frommer, Registration No. 25,506, Thomas J. Kowalski, Registration No. 32,147, and FROMMER LAWRENCE & HAUG, LLP or their duly appointed associates, my attorneys or agents, with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therewith, and to insert the Serial Number of the application in the space provided above, and specify that all communications about the application are to be directed to the following correspondence address:

William S. Frommer, Esq.  
Thomas J. Kowalski, Esq.  
c/o FROMMER LAWRENCE &  
HAUG, LLP  
745 Fifth Avenue  
New York, NY 10151  
FAX (212) 588-0500

Direct all telephone calls to: (212) 588-0800  
to the attention of:  
Thomas J. Kowalski

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S):

Signature: Date: 1<sup>st</sup> of March 2000Full name of first inventor: Sven BERGSTRÖMResidence: Mamorvägen 95  
S-907 42 Umeå, Sweden *SEX*Citizenship: Swedish

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of second inventor:

Residence:

Citizenship:

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of third inventor:

Residence:

Citizenship:

Post Office Address(es) of inventors [if different from residence]:

NOTE: In order to qualify for reduced fees available to Small Entities, each inventor and any other individual or entity having rights to the invention must also sign an appropriate separate "Verified Statement (Declaration) Claiming [or Supporting a Claim by Another for] Small Entity Status" form [e.g. for Independent Inventor, Small Business Concern, Nonprofit Organization, Individual Non-Inventor].

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: Symbicom AB
- (B) STREET: Tvistevägen 48
- (C) CITY: Umeå
- (E) COUNTRY: Sweden
- (F) POSTAL CODE (ZIP): S-907 36

(ii) TITLE OF INVENTION: Pl3 antigens from Borrelia

(iii) NUMBER OF SEQUENCES: 31

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Borrelia burgdorferi
- (B) STRAIN: B313

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Thr Ser Lys Gln Asp Pro Ile Val Pro Phe Leu Leu Asn Leu Phe Leu  
1 5 10 15

Gly Phe Gly Ile Gly Ser Phe Ala Gln  
20 25

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

















50                                      55                                      60  
 Ala Gln Gly Asp Ile Leu Gly Gly Ser Leu Ile Leu Gly Phe Asp Ala  
 65                                      70                                      75                                      80  
 Val Gly Ile Gly Leu Ile Leu Ala Gly Ala Tyr Leu Asp Ile Lys Ala  
                                     85                                      90                                      95  
 Leu Asp Gly Ile Thr Lys Lys Ala Ala Phe Gln Trp Thr Trp Gly Lys  
                                     100                                      105                                      110  
 Gly Val Met Leu Ala Gly Val Val Thr Met Ala Val Thr Arg Leu Thr  
                                     115                                      120                                      125  
 Glu Ile Ile Leu Pro Phe Thr Phe Ala Asn Ser Tyr Asn Arg Lys Leu  
                                     130                                      135                                      140  
 Lys Asn Ser Leu Asn Val Ala Leu Gly Gly Phe Glu Pro Ser Phe Asp  
 145                                      150                                      155                                      160  
 Val Ala Met Gly Gln Ser Ser Ala Leu Gly Phe Glu Leu Ser Phe Lys  
                                     165                                      170                                      175  
 Lys Ser Tyr  
                                     179

## (2) INFORMATION FOR SEQ ID NO: 20:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 862 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Borrelia afzelii*
- (B) STRAIN: ACAI

## (ix) FEATURE:





GCA GTT ACT ATG GCT GTG ACA AGA TTG ACA GAA ATT ATT ATT CCG TTT 617  
 Ala Val Thr Met Ala Val Thr Arg Leu Thr Glu Ile Ile Ile Pro Phe  
 120 125 130

ACA TTT GCT AAT AGT TAT AAT AGG AAA CTG AAA AAT AGC CTT AAT ATA 665  
 Thr Phe Ala Asn Ser Tyr Asn Arg Lys Leu Lys Asn Ser Leu Asn Ile  
 135 140 145

GCT TTT GGA GGG TTT GAG CCT AGT TTT GAT ATT AAT ATG GGC CAA GCT 713  
 Ala Phe Gly Gly Phe Glu Pro Ser Phe Asp Ile Asn Met Gly Gln Ala  
 150 155 160 165

AGC GCT CTT GGG TTT GAA CTA TCT TTC AAA AAA AGT TAT TAA 755  
 Ser Ala Leu Gly Phe Glu Leu Ser Phe Lys Lys Ser Tyr \*  
 170 175

TTTTATTTTA TTATTAAAT GAGTGATAGC AATTTTGTAT TGTGATTGCT CATTGTAATT 815

GAAAATTAGA GCTTTTGTTT ATTATTTATA TTTTATTCT CTGCTAA 862

## (2) INFORMATION FOR SEQ ID NO: 21:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 178 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Met Asn Lys Phe Leu Ile Val Val Leu Leu Ala Phe Cys Val Phe Ser  
 1 5 10 15

Ser Phe Ala Gln Ala Asp Asp Ser Lys Ser Ala Phe Asn Leu Gly Ala  
 20 25 30

Gly Glu Lys Leu Leu Ala Tyr Glu Thr Ser Lys Lys Asp Pro Ile Val  
 35 40 45

Pro Phe Leu Leu Asn Leu Phe Leu Gly Phe Gly Ile Gly Ser Phe Ala
















(2) INFORMATION FOR SEO ID NO: 31:

(A) LENGTH: 95 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(v) FRAGMENT TYPE: internal

```
Met Lys Lys Ile Phe Thr Leu Ile Leu Ile Phe Gly Leu Thr Ile Glu  
1          5          10          15  
  
Ile Phe Ala Thr Lys Asp Thr Gln Asn Arg Ile Glu Lys Gly Ile Glu  
          20          25          30  
  
Ser Phe Asn Lys Tyr Asp Lys Glu Lys Lys Asn Pro Ile Gly Pro Phe  
          35          40          45  
  
Leu Leu Asn Leu Phe Leu Pro Phe Gly Ile Gly Ser Phe Val Gln Gly  
          50          55          60  
  
Asp Tyr Ile Gly Gly Gly Ser Val Leu Gly Phe Asn Leu Leu Gly Ala  
        65          70          75          80  
  
Ile Leu Trp Glu Leu Glu Leu Phe Leu Ile Thr Glu Lys His Asn  
          85          90          95
```

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



SCAN 9

Application deficiencies were found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Scanned copy is best available.

*This case has only 3 pages of declaration.*